[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 322
1. Wang L, Hollenbeak CS, Stewart DB: Node yield and node involvement in young colon cancer patients: is there a difference in cancer survival based on age? J Gastrointest Surg; 2010 Sep;14(9):1355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Node yield and node involvement in young colon cancer patients: is there a difference in cancer survival based on age?
  • BACKGROUND: The effect on cancer-specific survival (CSS) from the number of resected nodes (node yield) and the number of nodes involved with colon cancer has not been studied with respect to age.
  • PATIENT AND METHODS: Data from 1992 to 2006 from the Surveillance, Epidemiology and End Results (SEER) registry were analyzed for colon cancer patients undergoing curative resection, comparing younger (< 40; n = 2,642) and older (> or = 40; n = 138,769) patients.
  • Younger patients were more likely to have metastatic disease and to have a nodal yield of > or = 12 nodes, and were less likely to have node-negative colon cancers (all p < 0.0001).
  • Younger age was associated with a lower risk of death from colon cancer (HR = 0.65; p < 0.0001).
  • Node yield < 12 created a higher risk of cancer-specific death (HR = 1.22; p < 0.0001) regardless of stage.
  • KM plots by stage demonstrated a CSS advantage (p < 0.0001) for younger patients.
  • CONCLUSIONS: Younger patients with colon cancers do not have a worse CSS simply because of their young age, so long as proper oncologic surgical principles are adhered to.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / mortality. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):205-14 [12555297.001]
  • [Cites] J Am Coll Surg. 1996 Aug;183(2):105-12 [8696540.001]
  • [Cites] Eur J Surg Oncol. 1994 Jun;20(3):225-31 [8181597.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Am Surg. 1998 Jun;64(6):563-7; discussion 567-8 [9619179.001]
  • [Cites] Am Surg. 1994 Aug;60(8):607-12 [8030817.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Dis Colon Rectum. 1982 Apr;25(3):209-14 [7067560.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):452 [11466702.001]
  • [Cites] Cancer. 1984 Oct 1;54(7):1478-81 [6467172.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2759-65 [17593332.001]
  • [Cites] Dis Colon Rectum. 1989 Oct;32(10):843-6 [2791769.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):180-3 [14530812.001]
  • [Cites] Surg Endosc. 1989;3(2):96-9 [2672395.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):904-10 [12847364.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):380-7 [11289284.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • (PMID = 20585992.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, Endo H, Shiratori Y: Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol; 2008 Mar;23(3):418-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology.
  • BACKGROUND AND AIM: Recently, the clinical and biological differences between right- and left-sided colon cancers have been widely debated.
  • METHODS: A total of 3552 consecutive Japanese colorectal cancer cases were examined and the clinical differences between right- and left-sided colon cancer cases were investigated.
  • RESULTS: The proportion of right-sided colon cancer was relatively high in patients aged less than 40 years (33%) and more than 80 years (43%).
  • The proportion of right-sided colon cancer in patients aged 40-59 years was relatively low (male 22% and female 29%).
  • Right-sided colon cancer was more likely to be detected at an advanced stage (T1 stage; left 22%, right 15%) (P < 0.01) with severe symptoms.
  • Polypoid-type early cancer was dominant in the left colon (left 59%; right 40%) (P < 0.01), while the proportion of flat-type early cancer in the right colon was significantly higher than that in the left colon (left 25%; right 44%) (P < 0.01).
  • CONCLUSIONS: Specific age distribution of right-sided colon cancer was observed and the difference between male and female patients was highlighted.
  • Other clinical features also differed between right- and left-sided colon cancer, suggesting that different mechanisms may be at work during right and left colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532785.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Australia
  •  go-up   go-down


3. Madbouly KM, Senagore AJ, Mukerjee A, Hussien AM, Shehata MA, Navine P, Delaney CP, Fazio VW: Colorectal cancer in a population with endemic Schistosoma mansoni: is this an at-risk population? Int J Colorectal Dis; 2007 Feb;22(2):175-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data collected included age, sex, clinical presentation, presence of synchronous tumors, histopathology, and clinical stage. p53, DCC (deleted in colorectal cancer gene), and mismatch repair genes (MLH1 and MSH2) were studied using immunohistochemical staining.
  • Mucinous adenocarcinoma occurred significantly more frequently in SCC (35 vs 10%, p=0.02).
  • SCC tumors were more frequently stage III or IV, and significantly more synchronous tumors were present in the affected group (SCC-8/40 vs NDCC-1/20, p=0.05).
  • CONCLUSION: The data suggest that schistosomal colitis is more commonly associated with earlier onset of multicentric colorectal cancer, high percentage of mucinous adenocarcinoma, and presents at an advanced stage.
  • [MeSH-major] Adenocarcinoma / parasitology. Colitis / parasitology. Colorectal Neoplasms / parasitology. Endemic Diseases. Schistosomiasis mansoni / complications

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Gastroenterol. 1993 Mar;31(3):192-7 [8386413.001]
  • [Cites] Eur J Surg Oncol. 1994 Jun;20(3):225-31 [8181597.001]
  • [Cites] Mutat Res. 1994 Mar 1;305(2):273-81 [7510038.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10 Suppl):S2-9 [9378007.001]
  • [Cites] Carcinogenesis. 1995 May;16(5):1181-9 [7767983.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):26-30 [9096661.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):38-43 [12604723.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1255-60 [12352245.001]
  • [Cites] Int J Cancer. 1984 Sep 15;34(3):315-8 [6480152.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1602-10 [1358743.001]
  • [Cites] Mt Sinai J Med. 2000 May;67(3):227-40 [10828908.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):32-6 [10700863.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1661-75 [7417960.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):811-6 [9714045.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):871-8 [10702404.001]
  • [Cites] J Natl Cancer Inst. 1990 Jun 6;82(11):915-26 [2342126.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):345-7 [10530603.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):349-54 [10530604.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):123-8 [3947149.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1037-46 [11592777.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1721-6 [10964104.001]
  • [Cites] Jpn J Clin Oncol. 1999 Nov;29(11):576-81 [10678562.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 16786317.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Nakao K, Tsunoda A, Amagasa H, Suzuki N, Yamazaki K, Kusano M: [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11]. Gan To Kagaku Ryoho; 2006 Jan;33(1):109-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
  • Pathological findings were type 3, 30 x 20 mm, poorly-differentiated adenocarcinoma, se, ly 2, v 2, n 2 (+), ow (-), aw(-), H 3, P 0 (stage IV).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Sobczuk A, Smolarz B, Romanowicz-Makowska H, Pertyński T: MMAC/PTEN gene expression in endometrial cancer: RT-PCR studies. Pol J Pathol; 2006;57(3):137-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the MMAC/PTEN (phosphatase and tensin homologue deleted on chromosome 10) gene are documented in cancers of the breast, prostate, ovary, colon, melanoma, glioblastoma, lymphoma and endometrium.
  • In the present work MMAC/PTEN gene expression in women with endometrial adenocarcinoma (n=70) in RNA samples obtained from cancer tissue were investigated.
  • The expression of MMAC/PTEN gene in endometrial adenocarcinoma cases was significantly reduced compared to the expression in the normal samples (P < 0.05).
  • Furthermore the significant difference (P < 0.05) was observed between the expression of MMAC/PTEN in stage III versus lower stages of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Gene Expression. PTEN Phosphohydrolase / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219740.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


6. Liang JT, Lai HS, Lee PH: Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it? Surg Endosc; 2006 Apr;20(4):695-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in colon cancer.
  • METHODS: Patients with lower rectal adenocarcinoma located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
  • Two patients were in pathologic TNM stage I, 14 in stage II, and six in stage III.
  • [MeSH-major] Abdomen / surgery. Adenocarcinoma / surgery. Laparoscopy / methods. Perineum / surgery. Rectal Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1481-5 [12432295.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5 [9660024.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):47-53 [10706303.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • (PMID = 16502195.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


7. Jestin P, Påhlman L, Glimelius B, Gunnarsson U: Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination. Eur J Cancer; 2005 Sep;41(14):2071-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination.
  • Correct staging of colon cancer is decisive regarding further oncological treatment, surveillance and prediction of long-term survival.
  • Data from the colon cancer register (1997-2002) of the Uppsala/Orebro, Sweden, health care region were analysed and the seven pathology departments in this region were compared.
  • Included were 3735 patients who had undergone resection of a colon cancer.
  • Survival in stage II was lower when fewer than 12 nodes were examined or when the number of nodes sampled was not given (P = 0.001, log-rank test).
  • In stage III, those with at the most 3 nodes positive (N1) had a better survival than those with 4 or more nodes positive (N2) (P < 0.001, log-rank test).
  • An index of metastases (IM), derived from the number of nodes with metastases divided by the number of nodes examined, was calculated for stage III tumours.
  • Examination of 12 nodes is necessary to assure stage III cases with the median IM (0.32), whereas 20 nodes are necessary to assure 90% of cases with the lower quartile of IM (0.16).
  • The prognostic information of the IM was higher than that of the N-stage.
  • An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125926.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Park YK, Kim DY, Joo JK, Kim JC, Koh YS, Ryu SY, Kim YJ, Kim SK: Clinicopathological features of gastric carcinoma patients with other primary carcinomas. Langenbecks Arch Surg; 2005 Aug;390(4):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Multiple primary carcinomas are increasingly being found because of the development of diagnostic techniques and the increasing incidence of early stage carcinoma.
  • RESULTS: Associated primary carcinomas were often found in the gastrointestinal (GI) tract, especially in the colon (33.8%).
  • In patients with gastric carcinoma only, poorly differentiated adenocarcinoma was the most common (43.2%), followed by moderately and well-differentiated adenocarcinoma.
  • Similarly, poorly differentiated adenocarcinoma (33.8%) was also the prevalent histological type in gastric carcinoma patients with other primary carcinomas, although its incidence was lower.
  • The stage of gastric carcinoma did not differ between the two groups.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Second Primary / epidemiology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):229-33 [7657384.001]
  • [Cites] Cancer. 1977 Oct;40(4 Suppl):1786-92 [332330.001]
  • [Cites] Cancer Cells. 1991 Feb;3(2):49-52 [2029453.001]
  • [Cites] J La State Med Soc. 1962 Jun;114:194-200 [14453808.001]
  • [Cites] J Surg Oncol. 1994 Jun;56(2):122-7 [8007677.001]
  • [Cites] Cancer. 1990 May 1;65(9):2091-100 [2372775.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):672-6 [8751233.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1535-49 [8482467.001]
  • [Cites] J Surg Oncol. 1994 Feb;55(2):95-9 [8121192.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):678-83 [10797290.001]
  • [Cites] Jpn J Clin Oncol. 1986 Dec;16(4):373-81 [3795533.001]
  • [Cites] Natl Cancer Inst Monogr. 1982;62:135-40 [7167176.001]
  • [Cites] Acta Oncol. 1991;30(1):1-6 [2009177.001]
  • [Cites] Jpn J Clin Oncol. 1985 Apr;15 Suppl 1:183-90 [4009981.001]
  • [Cites] J Urol. 1989 Jul;142(1):1-12 [2659818.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):1049-53 [7645924.001]
  • [Cites] Oncology. 2003;65(2):113-7 [12931016.001]
  • [Cites] Am J Surg. 1975 Jun;129(6):686-90 [1130613.001]
  • [Cites] Surg Clin North Am. 1990 Oct;70(5):1141-9 [2218824.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2889-94 [8221554.001]
  • [Cites] J Surg Oncol. 1995 Dec;60(4):277-81 [8551739.001]
  • (PMID = 15599757.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Widder J, Herbst F, Dobrowsky W, Schmid R, Pokrajac B, Jech B, Chiari C, Stift A, Maier A, Karner-Hanusch J, Teleky B, Wrba F, Jakesz R, Poetter R: Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II). Br J Cancer; 2005 Apr 11;92(7):1209-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) with clinical T3Nx rectal adenocarcinoma received preoperative pelvic radiation therapy with single fractions of 2.5 Gy twice daily (interval 6 h between fractions) to a total dose of 25 Gy within 1 week.
  • Postoperative histology revealed UICC stage I in 33%, stage II in 26%, stage III in 34%, and stage IV in 7% of the patients.
  • Disease-specific and disease-free survivals at 4 years (excluding stage IV) were 82 and 69%, respectively.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Neoplasm Recurrence, Local. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Acta Oncol. 1999;38(7):883-93 [10606418.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Radiother Oncol. 2000 Sep;56(3):341-7 [10974384.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):497-504 [11229667.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1429-36 [12110487.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4361-7 [12409336.001]
  • [Cites] Br Med Bull. 2002;64:141-57 [12421731.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Radiother Oncol. 1997 Aug;44(2):123-36 [9288840.001]
  • (PMID = 15785745.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361979
  •  go-up   go-down


10. McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY: Malignancies of the appendix: beyond case series reports. Dis Colon Rectum; 2005 Dec;48(12):2264-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients diagnosed with mucinous adenocarcinoma (n = 951), adenocarcinoma (n = 646), carcinoid (n = 435), goblet (n = 369), and signet-ring cell (n = 113) in the Surveillance, Epidemiology, and End Results database (1973-2001) were analyzed.
  • Evaluation of incidence, stage, and five-year relative survival were determined for each histology.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Appendiceal Neoplasms / pathology. Carcinoid Tumor / pathology. Carcinoma, Signet Ring Cell / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258711.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ: Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg; 2009 Jul;13(7):1292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For six patients who were operated upon because of tumor progression, the results were evaluated against the histological tumor stage.
  • In the six operated patients, T stage was correctly assessed in four of six patients by endoscopic ultrasound and in three of six patients by magnetic resonance imaging.
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / diagnostic imaging. Carcinoma, Squamous Cell / pathology. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / diagnostic imaging. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Jun 14;14 (22):3504-10 [18567078.001]
  • [Cites] Surg Endosc. 2008 Nov;22(11):2412-5 [18622554.001]
  • [Cites] Int J Colorectal Dis. 2000 Nov;15(5-6):282-90 [11151431.001]
  • [Cites] Endoscopy. 1995 Sep;27(7):469-79 [8565885.001]
  • [Cites] Surg Endosc. 2000 Nov;14 (11):1005-9 [11116406.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):895-900 [17352019.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Dis Colon Rectum. 1986 Apr;29(4):234-42 [3512199.001]
  • [Cites] Int J Colorectal Dis. 1991 Aug;6(3):152-7 [1744487.001]
  • [Cites] Clin Radiol. 2005 Oct;60(10):1111-9 [16179172.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):122-4 [1402307.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10 ):1261-8 [17294198.001]
  • [Cites] Int J Colorectal Dis. 1991 Feb;6(1):2-4 [2033348.001]
  • [Cites] Dis Colon Rectum. 1978 Mar;21(2):89-91 [648293.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):144-8 [16357394.001]
  • [Cites] Radiology. 2004 Sep;232(3):773-83 [15273331.001]
  • [Cites] Eur J Radiol. 2007 Mar;61(3):480-9 [17188828.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2491-9 [12815134.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1347-52 [17643251.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):191-9 [16799791.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]
  • [Cites] Dis Colon Rectum. 1974 Mar-Apr;17(2):181-7 [4819268.001]
  • [Cites] Radiol Med. 2003 Oct;106(4):329-37 [14612825.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]
  • [Cites] Radiology. 2007 Jan;242(1):137-43 [17090719.001]
  • [Cites] J Ultrasound Med. 2006 Jan;25(1):57-73 [16371556.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Radiology. 1990 May;175(2):494-8 [2326475.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19365694.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Lim SB, Choi HS, Jeong SY, Park JG: Feasibility of laparoscopic techniques as the surgical approach of choice for primary colorectal cancer: an analysis of 570 consecutive cases. Surg Endosc; 2008 Dec;22(12):2588-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the periods, the proportion of rectal cancer and right colon cancer increased (p < 0.001), T- and N-stage became more advanced (p < 0.001, p = 0.011 respectively), and operative time decreased (p < 0.001).
  • The short-term favorable outcomes support the feasibility of laparoscopic technique as surgical approach of choice for colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Mar;24(3):726-7 [19633895.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Surg Endosc. 2003 Apr;17(4):636-40 [12574925.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Arch Surg. 1997 Jan;132(1):41-4; discussion 45 [9006551.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1648-54 [12473889.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1111-24 [15449261.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1197-202 [16865622.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):83-91 [15973105.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1239-48 [16873440.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):369-74 [15932561.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):592-6 [9152190.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • [Cites] Dis Colon Rectum. 1995 Jun;38(6):600-3 [7774470.001]
  • (PMID = 19011948.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


13. Soumaoro LT, Uetake H, Takagi Y, Iida S, Higuchi T, Yasuno M, Enomoto M, Sugihara K: Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum; 2006 Mar;49(3):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue samples of primary tumors and metastatic lymph nodes from 150 patients undergoing intentionally curative surgical resections for colorectal adenocarcinoma were immunohistochemically examined for vascular endothelial growth factor-C, cyclooxygenase-2, and CD34 expressions.
  • A significant correlation was found between the expression scores of vascular endothelial growth factor-C and cyclooxygenase-2 (P < 0.0001), and both also were correlated to microvessels density and several clinicopathologic parameters, including primary tumor size, lymph node metastasis, lymphatic invasion, and TNM stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Lymph Nodes / metabolism. Membrane Proteins / metabolism. Vascular Endothelial Growth Factor C / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474989.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor C; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


14. Baton O, Lasser P, Sabourin JC, Boige V, Duvillard P, Elias D, Malka D, Ducreux M, Pocard M: Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study. World J Surg; 2005 Sep;29(9):1166-70, discussion 1171
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study.
  • Intraoperative sentinel lymph node (SLN) detection has been reported for colon cancer, but no study has focused on rectal cancer.
  • We evaluated SLN detection using blue dye injection in patients with rectal adenocarcinoma.
  • A micrometastasis was discovered in 3 of 23 pNO cases when H&E was used on multisection levels, thus changing the stage to pN1.
  • However, SLNs detection can change the tumor stage by upstaging nearly 15% of the tumors from T2-3N0 to T2-3 N+.
  • [MeSH-major] Adenocarcinoma / pathology. Rectal Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] Am J Surg. 2001 Dec;182(6):707-12 [11839343.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):120-4 [10761790.001]
  • [Cites] Arch Surg. 2000 Aug;135(8):926-32 [10922254.001]
  • [Cites] Ann Surg. 2001 Apr;233(4):515-21 [11303133.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1021-5; discussion 1025-6 [12907892.001]
  • [Cites] Surgery. 2001 Sep;130(3):439-42 [11562667.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):194-202 [9530893.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):850-4; discussion 854-6 [11391147.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):150-7 [11258780.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):917-20 [1717210.001]
  • [Cites] J Am Coll Surg. 2003 Jan;196(1):95-103 [12517559.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] J Surg Oncol. 2002 May;80(1):27-32; discussion 33 [11967903.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9 Suppl):94S-98S [11599912.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2 Suppl 1):S115-28 [10868902.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):410-7 [11289289.001]
  • [Cites] J Gastrointest Surg. 2002 May-Jun;6(3):322-9; discussion 229-30 [12022982.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1482-6 [9554524.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] Ann Chir. 2003 Sep;128(7):433-7 [14559191.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):637-42 [8891622.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):482-6 [10215818.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):977-85 [11978523.001]
  • [Cites] J Surg Oncol. 2002 Feb;79(2):81-4; discussion 85 [11815993.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):779-85 [12794580.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401 [8092905.001]
  • [Cites] Dis Colon Rectum. 1998 Jul;41(7):839-45 [9678368.001]
  • [Cites] Cancer J. 2002 Nov-Dec;8(6):445-50 [12500853.001]
  • (PMID = 16086211.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res; 2008 Oct 15;68(20):8541-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
  • In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers.
  • A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31).
  • These results remained significant in multivariate analysis adjusted for age, stage, and BRAF and KRAS mutational status [CIMP-Low: hazard ratio (HR), 1.85; 95% confidence interval (95% CI), 1.37-2.51; CIMP-High, HR, 2.90; 95% CI, 1.53-5.49 compared with No-CIMP].
  • Methylation is an independent prognostic factor in MSS colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. CpG Islands. DNA Methylation

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922929.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


16. Qureshi AU, Iqbal M, Gondal KM: Transhiatal esophageal surgery for malignancy--a 7-year experience at a tertiary care hospital. J Coll Physicians Surg Pak; 2009 Jul;19(7):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All underwent transhiatal esophagectomy and gastric tube or colon was used as the conduit to restore continuity.
  • The TNM staging were stage I, IIa, IIb, III and IV in zero (0), 5 (11%), 10 (22%), 24 (57.8%) and 3 (7.1%) respectively.
  • The frequency of complications is lower as compared to transthoracic approach and the early stage of presentation can lead to high 5-year survival ratios.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576147.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


17. Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano L, Jass JR: Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach. Hum Pathol; 2006 Aug;37(8):1022-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-seven samples of normal colon mucosa were included as a control group.
  • In contrast, cytoplasmic pAKT overexpression was associated with early T stage (P = .04), early N stage (P = .02), and absence of tumor budding (P = .03) only in the MLH1-negative group.
  • Dysregulation of the mitogen-activated protein kinase pathway is likely to be implicated in the mechanism of tumor budding only in MMR-proficient CRC, whereas the phosphoinositide 3-kinase/AKT pathway is associated with early stage in MLH1-negative CRC.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Mitogen-Activated Protein Kinases / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Colon / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Phosphorylation. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867865.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


18. Chang SC, Lin JK, Lin TC, Liang WY: Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol; 2005 Jan;26(1):65-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
  • Of these, 20 were stage I (12%), 54 stage II (32.3%), 58 stage III (34.7%), and 35 stage IV (21%).
  • Genetic p53 alterations were associated with advanced tumor stage and tumor differentiation.
  • Of 132 potentially cured patients, 3-year disease-free survival (DFS) was affected by: advanced TNM stage (I, II, III: 90%, 84%, and 41%), genetic p53 alteration (89% vs. 43%), intratumoral p53 accumulation (71% vs. 56%), and preoperative CEA level >5 ng/ml (74% vs. 58%).
  • In multivariate analysis, genetic alteration of p53 was the most significant independent prognostic factor [hazard ratio (HR) = 6.09; 95% confidence interval (CI): 2.45-15.11], followed by advanced tumor stage (HR = 3.93; 95% CI: 2.14-7.23), and preoperative CEA >5 ng/ml (HR = 1.98; 95% CI: 1.12-3.17).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Colorectal Neoplasms / diagnosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15586226.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


19. Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH, Choi D, Jang SJ: Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol; 2007 Dec;14(12):3453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
  • We investigated the expression of Apaf-1 in colorectal tissues corresponding to the multistep carcinogenesis model to determine correlations between the clinicopathologic characteristics and the expression of this molecule and to evaluate the role of Apaf-1 in the development and progression of colorectal adenocarcinoma.
  • In the analyses between Apaf-1 expression and clinicopathologic parameters, reduced expression of Apaf-1 correlated with left colon location (p < 0.001), deeper tumor invasion (p < 0.001), frequent lymph node metastasis (p = 0.021), higher American Joint Committee on Cancer (AJCC) and Dukes' stage (p = 0.02 and p = 0.001, respectively) and poorer differentiation (p < 0.001).
  • The patient survival was significantly associated with age, histological grade, AJCC stage, and lymphovascular invasion, but not Apaf-1 expression (p = 0.478).
  • CONCLUSIONS: The results suggest that the loss of Apaf-1 expression is a relatively frequent late event and the loss of Apaf-1 expression may play an important role in tumorigenesis and tumor progression in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882496.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • RESULTS: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from M0 to M1 leading to change the treatment intent from curative to palliative in a case.Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
  • Clinical stage variation occurred in 18.5% of cases with change of treatment intent in 3.7%.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


21. Borie F, Tretarre B, Marchigiano E, Daurcs JP, Millat B: Management and prognosis of colon cancer in patients with intestinal obstruction or peritonitis: a French population-based study. Med Sci Monit; 2005 Jun;11(6):CR266-273
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and prognosis of colon cancer in patients with intestinal obstruction or peritonitis: a French population-based study.
  • BACKGROUND: In spite of recent advances in our knowledge of tumor biology and therapy, the management and prognosis of patients with colon cancer (CC) revealed by intestinal obstruction or peritonitis (IOP) are not well defined.
  • The primary independent negative prognostic factor in multivariate analysis was the presence of nodal or distant metastases (Dukes' stage D, p=0.0001), followed by lack of chemotherapy (p=0.008), initial treatment in non-specialized hospitals (p=0.01), onset with IOP (p=0.02), low-volume surgeons (p=0.02).
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy. Intestinal Obstruction / etiology. Peritonitis / etiology

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15917717.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Poland
  •  go-up   go-down


22. Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF, Chen YT: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol; 2009 Apr;33(4):572-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety-two percent of tumors from young patients occurred in the distal colon (P=0.006), particularly the rectum (58%, P=0.02), and 75% were stage III or IV.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology


23. Cressey R, Wattananupong O, Lertprasertsuke N, Vinitketkumnuen U: Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer; 2005;5:128
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) The expression pattern of VEGF isoforms at the protein level in colorectal and lung adenocarcinoma in comparison to the pattern in corresponding adjacent normal tissues 2) The relationship between the expression pattern of VEGF and total level of circulating VEGF in the blood to clarify whether the results of measuring circulating VEGF can be used to predict VEGF expression in tumour tissues.
  • There was a significant correlation of the expression of VEGF165 with a smaller tumour size maximum diameter < 5 cm (p < 0.05), and there was a significant correlation of VEGF189 with advanced clinical stage of colorectal tumours.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Blotting, Western. Carcinoma, Squamous Cell / metabolism. Case-Control Studies. Cell Line, Tumor. Colon / metabolism. Colorectal Neoplasms / metabolism. Disease Progression. Enzyme-Linked Immunosorbent Assay. Humans. Lung / metabolism. Lung Neoplasms / metabolism. Middle Aged. Models, Statistical. Prognosis. Protein Isoforms. Time Factors. Tissue Distribution

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Mar;77(6):998-1002 [9528847.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):541-4 [9472090.001]
  • [Cites] Br J Cancer. 1997;76(8):1041-5 [9376264.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12081-7 [9342366.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3891-4 [8752153.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):785-90 [8631593.001]
  • [Cites] Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):753-9 [7573238.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 13;215(2):750-6 [7488018.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11322-6 [7744769.001]
  • [Cites] Placenta. 1994 Jul;15(5):557-61 [7997455.001]
  • [Cites] Mol Biol Cell. 1993 Dec;4(12):1317-26 [8167412.001]
  • [Cites] Biochim Biophys Acta. 1994 Mar 31;1221(2):211-4 [8148401.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] J Cell Biochem. 1991 Nov;47(3):211-8 [1791185.001]
  • [Cites] Curr Mol Med. 2003 Dec;3(8):673-91 [14682490.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Sep 22;110 Suppl 1:S10-8 [12965086.001]
  • [Cites] Histol Histopathol. 2002;17(3):961-72 [12168808.001]
  • [Cites] Cytokine. 2002 May 21;18(4):191-8 [12126641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6023-8 [11972026.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):87-96 [11471901.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):617-23 [11274009.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):432-41 [11208836.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(19):7282-91 [10982845.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):133-7 [10211101.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1089-93 [10533453.001]
  • [Cites] Clin Exp Immunol. 2000 Jan;119(1):182-8 [10606981.001]
  • (PMID = 16202150.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1262699
  •  go-up   go-down


24. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM: C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med; 2005 Mar 15;142(6):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While a recent prospective study observed a positive association between C-reactive protein (CRP), a marker of inflammation, and risk for colon cancer, data testing this hypothesis are sparse.
  • MEASUREMENTS: Self-reported incident colorectal adenocarcinoma confirmed by medical record review.
  • High CRP levels were also not associated with increased risk in analyses done according to tumor location and stage at diagnosis, according to alternative cutoff points for CRP, or in any of the subgroups evaluated.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / etiology. C-Reactive Protein / metabolism. Colorectal Neoplasms / blood. Colorectal Neoplasms / etiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Intern Med. 2005 Mar 15;142(6):I79 [15767616.001]
  • [CommentIn] Ann Intern Med. 2005 Oct 4;143(7):544; author reply 544 [16204172.001]
  • (PMID = 15767620.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-47988; United States / NCI NIH HHS / CA / CA096619; United States / NHLBI NIH HHS / HL / HL-43851
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


25. Sjo OH, Larsen S, Lunde OC, Nesbakken A: Short term outcome after emergency and elective surgery for colon cancer. Colorectal Dis; 2009 Sep;11(7):733-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short term outcome after emergency and elective surgery for colon cancer.
  • OBJECTIVE: Emergency presentation of colon cancer is common and associated with high mortality and morbidity following surgical treatment.
  • METHOD: All patients with adenocarcinoma of the colon diagnosed between 1993 and 2007 were registered prospectively.
  • Multivariate analyses demonstrated that emergency operation, increasing age, advanced tumour stage and ASA class IV were independent risk factors for postoperative mortality.
  • CONCLUSION: Emergency operation for colon cancer was associated with high rates of complications and mortality, indicating that immediate surgery should be avoided if possible.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / adverse effects. Colonic Neoplasms / surgery. Colostomy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18624817.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Jakob C, Liersch T, Meyer W, Becker H, Baretton GB, Aust DE: Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol; 2008 Feb 21;14(7):1060-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Formalin fixed, paraffin embedded pre-therapeutical tumor biopsies (n = 22) and post-therapeutical resection specimens (n = 40) from patients with rectal adenocarcinoma (clinical UICC stage II/III) receiving standardized neoadjuvant 5-fluorouracil (5-FU) based chemoradiotherapy were studied for Ki67 and p53 expression by immunohistochemistry and correlated with TS mRNA expression by quantitative TaqMan real-time PCR after laser microdissection.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Ki-67 Antigen / metabolism. Rectal Neoplasms / metabolism. Rectal Neoplasms / pathology. Thymidylate Synthase / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):131-5 [12115559.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):277-83 [17211470.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):504-11 [12584750.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):529-36 [14752076.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2158-67 [15041737.001]
  • [Cites] Cancer Lett. 2004 Jul 8;210(1):101-9 [15172127.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5572-7 [10554037.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):560-7 [10682666.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):971-5 [10910245.001]
  • [Cites] Cancer J. 2000 Jul-Aug;6(4):234-42 [11038143.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):999-1009 [11309351.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5193-201 [11431359.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1937-43 [11747337.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):294-303 [11872273.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2832-43 [12065560.001]
  • [Cites] Cytometry. 2002 May 1;48(1):6-13 [12116375.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):879-88 [1855188.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):79-84 [1727928.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] N Engl J Med. 1994 Apr 21;330(16):1136-42 [8133857.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):681-7 [8158699.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2043-50 [7931472.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1151-7 [7779704.001]
  • [Cites] J Natl Cancer Inst. 1996 Feb 21;88(3-4):173-82 [8632491.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1149-58 [9515799.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1227-34 [9607581.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1405-11 [9815825.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3505-11 [10416617.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):263-9 [10430607.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] J Pathol. 2004 Dec;204(5):562-8 [15538739.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2114-21 [15956964.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1304-9 [16160472.001]
  • [Cites] Eur J Surg Oncol. 2006 Feb;32(1):55-64 [16324817.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1169-74 [16931962.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • (PMID = 18286688.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2689409
  •  go-up   go-down


27. Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA: Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol; 2009 Dec 10;27(35):5938-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical application of a calculator for conditional survival in colon cancer.
  • In this study we performed a contemporary evaluation of conditional survival among colon cancer patients and created a browser-based tool for real-time determination of conditional survival expectancies.
  • PATIENTS AND METHODS: Patients with colon adenocarcinoma diagnosed between 1988 and 2000 were identified from the Surveillance Epidemiology End Results (SEER) registry.
  • Conditional survival estimates were calculated by using the multiplicative law of probability after adjustment for age; sex; ethnicity; grade; and American Joint Commission on Cancer, sixth edition stage.
  • As the time alive after initial treatment increased from 0 to 5 years, significant improvements in CS were observed for patients in all stages except stage I, which was associated with good CS even at diagnosis and which reflected the high likelihood of cure.
  • Notably, adjusted 5-year CS rates improved from 42% to 80% for stage IIIC cancers and from 5% to 48% for stage IV cancers during the first 5 years.
  • CONCLUSION: For patients with colon cancer who survive over time, 5-year, cancer-specific CS improved dramatically, and the greatest improvements were among patients with poorer initial prognoses.
  • [MeSH-major] Adenocarcinoma / mortality. Colonic Neoplasms / mortality. Health Status Indicators

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC: The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res; 2008 Jun 15;14(12):3814-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer.
  • PURPOSE: The association hepatocyte growth factor receptor (Met) tyrosine kinase with prognosis and survival in colon cancer is unclear, due in part to the limitation of detection methods used.
  • EXPERIMENTAL DESIGN: Fluorescent-based IHC for Met was done in 583 colon cancer patients in a tissue microarray format.
  • RESULTS: In crossvalidated and univariate Cox analysis, the membrane relative to cytoplasm Met score was a significant predictor of survival in stage I (hazard ratio, 0.16; P = 0.006) and in stage II patients (hazard ratio, 0.34; P < or = 0.0005).
  • Met in the membrane alone was not a significant predictor of outcome in all patients or within stage.
  • CONCLUSIONS: These data indicate that the relative subcellular distribution of Met, as measured by novel automated image analysis, may be a valuable biomarker for estimating colon cancer prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Cell Membrane / metabolism. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins / metabolism. Receptors, Growth Factor / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559601.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


29. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


30. Grabowski P, Sturm I, Schelwies K, Maaser K, Buhr HJ, Dörken B, Zeitz M, Daniel PT, Scherübl H: Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis. Int J Colorectal Dis; 2006 Apr;21(3):221-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis.
  • Moreover, an altered p53/BAX pathway is associated with a poor clinical outcome in Union Internationale Contre le Cancer (UICC) stage III disease.
  • PATIENTS AND METHODS: Specimens were analyzed from 59 patients with UICC stage III disease who underwent surgery for colorectal adenocarcinoma at our institution and were followed up for 5 years or until death.
  • RESULTS: p53 status/BAX expression and neuroendocrine differentiation are not correlated in stage III colorectal cancers.
  • Both represent independent prognostic markers in UICC stage III disease.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1994 Sep 15;733:46-55 [7978895.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1022-32 [11455969.001]
  • [Cites] Int J Cancer. 2000 Aug 15;87(4):517-21 [10918191.001]
  • [Cites] Acta Oncol. 1993;32(2):115-24 [8323752.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3205-9 [12374690.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2035-44 [11187890.001]
  • [Cites] Essays Biochem. 2003;39:73-88 [14585075.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):281-6 [11004681.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):651-8 [11237386.001]
  • [Cites] Int J Cancer. 2002 Jun 1;99(4):589-96 [11992551.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):754-8 [7560204.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Ann Surg Oncol. 1996 Nov;3(6):574-9 [8915491.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):765-71 [8100808.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]
  • [Cites] Cell. 1997 Nov 14;91(4):479-89 [9390557.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1859-61 [2004298.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2749-60 [11420687.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):253-9 [11299743.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Jun;10(6):1011-9 [11772231.001]
  • [Cites] Gut. 2004 Jun;53(6):899-910 [15138220.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] APMIS. 2004 Jan;112(1):49-56 [14961975.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):403-9 [11802199.001]
  • [Cites] World J Surg. 2002 Jan;26(1):59-66 [11898035.001]
  • [Cites] Cancer. 1992 Jun 1;69(11):2641-6 [1571893.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):523-33 [11330579.001]
  • [Cites] Eur J Clin Invest. 1998 Dec;28(12):1038-49 [9893017.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1364-74 [10334520.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1766-75 [14583782.001]
  • [Cites] Physiol Rev. 1988 Apr;68(2):456-502 [3282244.001]
  • [Cites] Digestion. 2000;62 Suppl 1:3-18 [10940682.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1713-9 [14593113.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):445-54 [12478659.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):645-51 [7860139.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4573-81 [10969809.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(5):293-6 [8287125.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27643-50 [12011069.001]
  • [Cites] Histopathology. 1998 Feb;32(2):133-8 [9543669.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jan;125(1):91-8 [11151060.001]
  • [Cites] Arch Pathol Lab Med. 1998 Oct;122(10):912-4 [9786353.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3391-401 [12885834.001]
  • (PMID = 16485142.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / bcl-2-Associated X Protein
  •  go-up   go-down


31. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • With strict patient selection, it is oncologically safe for early-stage rectal carcinomas.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Assumpcao L, Choti MA, Gleisner AL, Schulick RD, Swartz M, Herman J, Gearhart SL, Pawlik TM: Patterns of recurrence following liver resection for colorectal metastases: effect of primary rectal tumor site. Arch Surg; 2008 Aug;143(8):743-9; discussion 749-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: Patients with rectal adenocarcinoma are at increased risk of locoregional recurrence compared with patients with colon cancer.
  • This may affect the pattern of recurrence and survival rates following hepatic resection of liver metastases from rectal adenocarcinoma.
  • PATIENT AND METHODS: From April 1, 1984, to December 31, 2005, 582 patients with liver metastases from a primary colorectal adenocarcinoma underwent hepatic resection.
  • Most rectal tumors were pathological stage T3/T4 (85.8%) and N1 (68.1%).

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):20-3 [9066742.001]
  • [Cites] Eur J Surg Oncol. 1998 Dec;24(6):528-35 [9870729.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):514-23 [10528899.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):900-9 [16184442.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] J Surg Oncol. 2007 May 1;95(6):447-54 [17048237.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):18-24 [10813118.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Br J Surg. 2001 Sep;88(9):1221-7 [11531871.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1682-8 [11711742.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):313-27 [15019929.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] ANZ J Surg. 2004 Sep;74(9):745-50 [15379800.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Cancer. 1983 Oct 1;52(7):1317-29 [6192900.001]
  • [Cites] Arch Surg. 1984 Jun;119(6):647-51 [6732473.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1408-16 [3345493.001]
  • [Cites] Arch Surg. 1990 Jun;125(6):718-21; discussion 722 [2346374.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Ann Surg. 1997 Jan;225(1):51-60; discussion 60-2 [8998120.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • (PMID = 18711033.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR025006; United States / NCRR NIH HHS / RR / 1KL2RR025006-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS411709; NLM/ PMC3488856
  •  go-up   go-down


33. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM: Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum; 2009 Jun;52(6):1039-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.
  • This study evaluated the disparity in neoplastic changes between colon and rectal cancers.
  • METHODS: A clinic-based colorectal frozen tumor bank at a single institution was queried for colon and rectal adenocarcinomas.
  • RESULTS: The 268 patients with colon cancer and 89 with rectal cancer were similar in gender, tumor size, stage, and differentiation.
  • Colon cancers had a higher incidence of microsatellite instability (27 percent) and methylator phenotype (28 percent) compared with rectal cancers (7 percent, 3 percent, respectively; P < 0.001).
  • Although KRAS mutation rate was similar, colon cancers had a higher incidence of BRAF mutations (16.7 percent vs. 0 percent; P < 0.001).
  • Despite overall differences in outcome between colon and rectal cancers, no significant difference in survival existed when similar molecular phenotypes were compared across anatomic sites.
  • CONCLUSIONS: Although colon cancers are molecularly heterogeneous, rectal cancers arise mostly via a single neoplastic pathway.
  • Genetic and molecular differences influence prognosis more than anatomic location and suggest that oncogenic pathways contribute to survival differences between colon and rectal cancers.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581844.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


34. Wang MS, Pan Y, Liu N, Guo C, Hong L, Fan D: Overexpression of DARPP-32 in colorectal adenocarcinoma. Int J Clin Pract; 2005 Jan;59(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of DARPP-32 in colorectal adenocarcinoma.
  • Our aim is to investigate the expression of DARPP-32 protein in colorectal adenocarcinoma.
  • The expression of DARPP-32 in colorectal adenocarcinoma tissues 33/42, 78.57% was higher than that in normal colon epithelial tissues (31/60, 51.67%, p <0.05).
  • There was no significant relationship between the expression of DARPP-32 and the differentiation, metastasis and Dukes' stage of colorectal adenocarcinoma (p >0.05).
  • Both DARPP-32 and its truncated isoform t-DARPP were overexpressed in colorectal adenocarcinoma (t=2.306, p=0.028), while t-DARPP was more frequently detected.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Nerve Tissue Proteins / metabolism. Phosphoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707466.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / Nerve Tissue Proteins; 0 / Phosphoproteins
  •  go-up   go-down


35. Sézeur A, Châtelet FP, Cywiner Ch, de Labriolle-Vaylet C, Chastang C, Billotey C, Malafosse M, Gallot D, Betton P, Montravers F, Carvajal-Gonzalez S, Askienazy S, Talbot JN, Rain JD, Milhaud G, Saumon G, Barbet J, Gruaz-Guyon A: Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging. Clin Cancer Res; 2007 Sep 15;13(18 Pt 2):5592s-5597s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology underrates colon cancer extranodal and nodal metastases; ex vivo radioimmunodetection helps staging.
  • The benefit of adjuvant chemotherapy for patients upstaged with radioimmunodection should also be assessed because adjuvant chemotherapy improves the 5-year survival of stage III patients.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Indium Radioisotopes. Radioimmunodetection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875794.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Carcinoembryonic Antigen; 0 / Haptens; 0 / Indium Radioisotopes; 0 / Oligopeptides
  •  go-up   go-down


36. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG: Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor? World J Surg; 2010 May;34(5):1102-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
  • BACKGROUND: Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases.
  • We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1269-76 [17318552.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):592-8 [18936572.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2283-92 [12436433.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5910-7 [19018087.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):35-41 [18987915.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Oncologist. 1999;4(3):197-208 [10394588.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1829-35 [18662955.001]
  • (PMID = 20177683.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. van Leeuwen BL, Påhlman L, Gunnarsson U, Sjövall A, Martling A: The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. Crit Rev Oncol Hematol; 2008 Sep;67(3):229-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.
  • RATIONALE: The aim of this study was to assess whether there are differences in treatment strategy and outcome between different age cohorts among men and women with colon cancer.
  • METHODS: All patients with colon cancer included in the regional quality registry in Uppsala/Orebro and Stockholm between 1996 and December 2004 were analysed (n=11002).
  • RESULTS: Overall and cancer-specific survival decreased with increasing age for stages II and III colon cancer but was not influenced by gender.
  • Older patients with stage III tumours were less likely to be referred for chemotherapeutic treatment and there was a decrease in cancer-specific survival with increasing age, from 63.7% to 51.0% to 38.4% in the three age groups.
  • [MeSH-minor] Adenocarcinoma. Age Distribution. Age Factors. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Sex Factors. Survival Analysis. Sweden. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440820.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


38. Zivković V, Katić V, Dordević B, Krstić M, Pejović S, Petrović A: [Clinico-pathological characteristics of colonic carcinoma in relation to localization and histologic type]. Vojnosanit Pregl; 2007 Dec;64(12):827-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From pathological report we used data regarding: localization (right or left colon), histological type, histological grade, and parameters which determinate the tumor stage.
  • There were no statistically significant differences between the right-sided and left-sided colonic carcinoma regarding sex, age, histological grade and tumor stage (p > 0.05).
  • Mucinous adenocarcinomas was statistically significantly more frequent in right-sided colon (35.00%) than in left-sided colon (16.67%) (p < 0.05).
  • There were no statistically significant differences between adenocarcinomas and mucinous adenocarcinomas regarding sex and disease stage.
  • CONCLUSION: According to the presented results it can be concluded that the lower grade of differentiation of the colon adenocarcinoma and mucinous secretion are significantly often present in younger patients.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357906.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


39. Box B, Lindsey I, Wheeler JM, Warren BF, Cunningham C, George BD, Mortensen NJ, Jones AC: Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients. Dis Colon Rectum; 2005 Jun;48(6):1153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were more locally advanced cancers in anemic (48 percent T4) compared with nonanemic patients (21 percent T4), but radiologic T stage did not influence tumor response (50 percent T3 vs. 43 percent T4 regression Grade 1, P = 0.53) or overall survival.
  • CONCLUSIONS: Patients with normal hemoglobin during chemoradiotherapy achieved better tumor response, less local recurrence, and improved overall survival compared with anemic patients, independent of radiologic T stage.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / therapy. Anemia / complications. Neoadjuvant Therapy. Rectal Neoplasms / complications. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868236.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


40. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection. Surg Endosc; 2009 Aug;23(8):1818-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local recurrence and metastasis were similar by stage.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Laparotomy. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Feb;25(2):658-60 [20632188.001]
  • [CommentIn] Surg Endosc. 2009 Dec;23(12):2871-3 [19688396.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):126-34 [11884047.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] J Am Coll Surg. 1997 Aug;185(2):105-13 [9249076.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):375-88 [16684081.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005200 [17054246.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):353-8 [16495700.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):374-9 [11289283.001]
  • [Cites] Br J Surg. 1998 Mar;85(3):355-8 [9529492.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):7-13 [11961595.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):284-91 [10336809.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1110 [8869318.001]
  • [Cites] Br J Surg. 2003 Apr;90(4):445-51 [12673746.001]
  • [Cites] Surg Endosc. 2005 Nov;19(11):1468-74 [16222464.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):308-11 [2021845.001]
  • [Cites] Surg Endosc. 2005 Nov;19(11):1460-7 [16206013.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2224-31 [16228823.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):413-24 [16450220.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 19118433.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


41. Melis M, Hernandez J, Siegel EM, McLoughlin JM, Ly QP, Nair RM, Lewis JM, Jensen EH, Alvarado MD, Coppola D, Eschrich S, Bloom GC, Yeatman TJ, Shibata D: Gene expression profiling of colorectal mucinous adenocarcinomas. Dis Colon Rectum; 2010 Jun;53(6):936-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous adenocarcinomas were more likely to be diagnosed with lymph node (LN) metastases (75% vs 51%, P = .04) and at a more advanced stage (85% vs 54%, P = .006) but long-term survival (5-y survival 58.9% vs 58.7%, P = NS) was similar.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Colorectal Neoplasms / genetics. Gene Expression Profiling

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485009.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP3 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 158801-98-0 / Aquaporin 3
  •  go-up   go-down


42. Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, Trutt B: Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):852-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).
  • METHODS: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.
  • 37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not.
  • CONCLUSION: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Colon / pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885869.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


43. Christoforidis D, Cho HM, Dixon MR, Mellgren AF, Madoff RD, Finne CO: Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. Ann Surg; 2009 May;249(5):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare transanal endoscopic microsurgery (TEMS) with conventional transanal excision (TAE) in terms of the quality of resection, local recurrence, and survival rates in patients with stage I rectal cancer.
  • METHODS: We retrospectively reviewed information on all patients with stage pT1 and pT2 rectal adenocarcinoma who underwent local excision from 1997 through mid-2006.
  • We found no significant differences in patient characteristics, adjuvant therapy, tumor stage, or adverse histopathologic features.
  • In our multivariate analysis, the tumor distance from the anal verge, the resection margin status, the T stage, and the use of adjuvant therapy--but not the surgical technique (i.e., TEMS or TAE) itself--were independent predictors of local recurrence and DFS.
  • [MeSH-major] Adenocarcinoma / surgery. Endoscopy, Digestive System. Neoplasm Recurrence, Local. Rectal Neoplasms / surgery


44. Kim SS, Ahn CH, Kang MR, Kim YR, Kim HS, Yoo NJ, Lee SH: Expression of CARD6, an NF-kappaB activator, in gastric, colorectal and oesophageal cancers. Pathology; 2010 Jan;42(1):50-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By contrast, corresponding normal epithelial cells of oesophagus (0%), stomach (8.0%) and colon (5.0%) displayed lower frequencies of CARD6 immunostaining.
  • The CARD6 expression was evident from an early TNM stage (stage I).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Count. Female. Fluorescent Antibody Technique, Direct. Humans. Male. Middle Aged. Signal Transduction. Tissue Array Analysis


45. Kong AP, Kim J, Holt A, Konyalian V, Huynh R, Udani SM, Stamos MJ, Kumar RR: Selective treatment of rectal cancer with single-stage coloanal or ultralow colorectal anastomosis does not adversely affect morbidity and mortality. Int J Colorectal Dis; 2007 Aug;22(8):897-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective treatment of rectal cancer with single-stage coloanal or ultralow colorectal anastomosis does not adversely affect morbidity and mortality.
  • RESULTS/FINDINGS: Forty-nine patients (78% preoperatively irradiated) were treated with a one-stage operation, whereas 17 (53% preoperatively irradiated) underwent reconstruction with proximal diversion.
  • The mean anastomotic height for patients with a single stage procedure was 3.8 cm above the anal verge versus 2.6 for patients with a two-stage procedure (p = 0.076).
  • With regard to anastomotic-associated complications for single stage versus two stage, complication rates were 8% versus 18%, respectively (p = 0.27).
  • INTERPRETATION/CONCLUSION: Low pelvic anastomoses in rectal cancer patients can be safely performed as a single-stage procedure, reserving the use of diversion for select cases.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colon / surgery. Digestive System Surgical Procedures / methods. Rectal Neoplasms / surgery. Rectum / surgery. Surgical Stomas

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2000 Feb;179(2):92-6 [10773140.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):253-65 [11969237.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):60-2 [8653367.001]
  • [Cites] J Am Coll Surg. 1997 Aug;185(2):105-13 [9249076.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):211-6 [15584062.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):940-5 [12130884.001]
  • [Cites] Acta Chir Iugosl. 2002;49(2):67-71 [12587473.001]
  • [Cites] Ann Surg. 1996 Jul;224(1):58-65 [8678619.001]
  • [Cites] Br J Surg. 1991 Feb;78(2):196-8 [2015471.001]
  • [Cites] Br J Surg. 1998 Mar;85(3):355-8 [9529492.001]
  • [Cites] Int J Colorectal Dis. 1987 Nov;2(4):214-7 [3320231.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):139-49 [15036189.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):1898-902 [14696429.001]
  • [Cites] Br J Surg. 1993 Jul;80(7):924-7 [8369941.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):973-6 [11978522.001]
  • [Cites] Am Surg. 2004 Dec;70(12):1045-9 [15663042.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):462-9 [15521937.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1164-71 [12352230.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s79-81 [15655652.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1261-6 [14515297.001]
  • [Cites] Dis Colon Rectum. 1995 May;38(5):480-6; discussion 486-7 [7736878.001]
  • [Cites] Eur J Surg. 1994 May;160(5):293-7; discussion 299-300 [8075199.001]
  • (PMID = 17361396.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Brosens RP, Oomen JL, Glas AS, van Bochove A, Cuesta MA, Engel AF: POSSUM predicts decreased overall survival in curative resection for colorectal cancer. Dis Colon Rectum; 2006 Jun;49(6):825-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk factors for overall survival were advanced stage of disease, poor tumor differentiation, mucinous adenocarcinoma, older than age 70 years, and poor condition of the patient at time of operation.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Severity of Illness Index

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550320.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Suzuki H, Yamamoto K, Hayashi S, Shindo H, Tonouchi A, Yamamori H: [A case of metastatic submandibular lymphnode treated successfully with palliative oral (5-FU + PSK) chemotherapy in the elderly]. Gan To Kagaku Ryoho; 2005 Jun;32(6):863-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was a 87-year-old woman diagnosed as type 2 advanced colon cancer in the ascending colon.
  • The pathological diagnosis showed poorly-differentiated adenocarcinoma, si, ly2, v1, n0 (0/41) and Stage IIIa.
  • Aspiration cytology of the lymph node indicated poorly-differentiated adenocarcinoma, and she was diagnosed as recurrent colon cancer.
  • We conclude that palliative oral (5-FU+PSK) chemotherapy is useful for recurrent colon cancer in the elderly because of its excellent safety and effectiveness.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Lymph Nodes / pathology

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984533.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proteoglycans; 66455-27-4 / krestin; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Neufeld D, Shpitz B, Bugaev N, Grankin M, Bernheim J, Klein E, Ziv Y: Young-age onset of colorectal cancer in Israel. Tech Coloproctol; 2009 Sep;13(3):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Younger patients displayed a higher percentage of mucinous cancers and a higher percentage of diagnosis at an advanced stage of disease; 40% of young-onset versus 31% of older-onset patients presented Duke's stages C and D (P = 0.02).
  • CONCLUSIONS: Younger age of onset colorectal cancer in our cohort of Israeli patients is associated with higher percentage of Arab patients, mucinous cancers, female gender, and advanced stage at diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):205-14 [12555297.001]
  • [Cites] Br Med Bull. 2002;64:1-25 [12421722.001]
  • [Cites] Am Surg. 1998 Sep;64(9):849-53 [9731812.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Fam Cancer. 2004;3(3-4):207-14 [15516843.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):204-7 [11197253.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):343-8 [15006562.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1222-6 [11005487.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):356-60 [10956410.001]
  • [Cites] Tech Coloproctol. 2008 Mar;12(1):21-5 [18512008.001]
  • [Cites] Gastroenterology. 1991 Apr;100(4):1033-40 [2001800.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):188-95 [12168965.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1037-46 [11592777.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):904-10 [12847364.001]
  • [Cites] Arch Med Res. 2003 Mar-Apr;34(2):152-3 [12700014.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):219-28 [11852336.001]
  • (PMID = 19609485.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


49. Talvinen K, Tuikkala J, Grönroos J, Huhtinen H, Kronqvist P, Aittokallio T, Nevalainen O, Hiekkanen H, Nevalainen T, Sundström J: Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer Res; 2006 Nov-Dec;26(6C):4745-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical and clinical approaches in evaluating the prognosis of colon cancer.
  • BACKGROUND: Colorectal adenocarcinoma is a common malignant neoplasm in the Western world.
  • CONCLUSION: Tumour stage is superior in estimating the prognosis of patients with colonic cancer compared with the grading of cell cycle regulators or histological grade of the cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214335.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human; EC 3.1.3.16 / CDC25B protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  •  go-up   go-down


50. Farhat MH, Barada KA, Tawil AN, Itani DM, Hatoum HA, Shamseddine AI: Effect of mucin production on survival in colorectal cancer: a case-control study. World J Gastroenterol; 2008 Dec 7;14(45):6981-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the impact of mucin production on prognosis in colorectal cancer, in terms of overall survival (OS) and time to disease progression (TTP) in patients with mucinous compared to those with non-mucinous colorectal cancer (NMCRC), matched for age, gender, and tumor stage.
  • METHODS: Thirty five patients with mucinous colorectal cancer (MCRC) were matched for age, gender, and tumor stage with 35 controls having NMCRC.
  • Twenty-eight percent of patients with MCRC had poorly differentiated adenocarcinoma versus 8.6% in NMCRC patients (P=0.028).
  • A larger study matching for stage and grade is needed.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / mortality. Mucins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1992 Sep;51(1):60-4 [1325577.001]
  • [Cites] Arch Pathol Lab Med. 1991 Oct;115(10):1022-5 [1654871.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):257-61 [8396358.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Jan;11(1):77-81 [8672747.001]
  • [Cites] J Pathol. 1997 Aug;182(4):380-4 [9306957.001]
  • [Cites] Rev Esp Enferm Dig. 1998 Aug;90(8):563-72 [9780789.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1057-61 [10339657.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s123-5 [15655594.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):259-64 [15655543.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1305-10 [15857840.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):70-4 [10694641.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] J Surg Oncol. 2000 Oct;75(2):103-7 [11064389.001]
  • [Cites] Gastroenterol Hepatol. 2002 Nov;25(9):534-40 [12435303.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):78-85 [14719155.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Jul;31(7):1053-6 [15272584.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):715-8 [2994793.001]
  • [Cites] Histopathology. 1987 Mar;11(3):259-72 [2828216.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):49-54 [8380140.001]
  • (PMID = 19058335.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  • [Other-IDs] NLM/ PMC2773863
  •  go-up   go-down


51. Wang H, Safar B, Wexner SD, Denoya P, Berho M: The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy. Dis Colon Rectum; 2009 Oct;52(10):1767-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy.
  • N1 and N2 stages were regarded as N+ stage.
  • In the nonneoadjuvant group, there was no significant difference in the number of positive lymph nodes (0.5 +/- 0.2 vs. 1.0 +/- 0.3, P = 0.235), N stage (P = 0.265), or patients with N+ stage (7/31 vs. 16/49, P = 0.332) between the two methods, even though the total lymph node harvest was significantly increased by use of the fat clearance method (9.6 +/- 1.3 vs. 27.6 +/- 2.5, P < 0.001).
  • In contrast, the total lymph node retrieval (5.2 +/- 0.6 vs. 20.4 +/- 1.2, P < 0.001), number of positive lymph nodes (0.4 +/- 0.2 vs. 1.2 +/- 0.3, P = 0.007), N stage (P = 0.005), and patients with N+ stage (6/51 vs. 34/106, P = 0.006) were all increased by fat clearance in the neoadjuvant group.
  • Moreover, the number of patients with N+ stage was stratified by T stage level (T0-T4) to eliminate the background bias, and the results were confirmed.
  • [MeSH-major] Adenocarcinoma / pathology. Lymph Node Excision / methods. Rectal Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966611.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Liu YL, Matsuzaki T, Nakazawa T, Murata S, Nakamura N, Kondo T, Iwashina M, Mochizuki K, Yamane T, Takata K, Katoh R: Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues. Hum Pathol; 2007 Jan;38(1):171-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No AQP3 expression was demonstrated in small cell carcinoma, pleomorphic carcinoma, or metastatic colon adenocarcinoma.
  • In addition, AQP3 expression was related to tumor differentiation and clinical stage in adenocarcinomas.
  • Western blotting and reverse transcriptase-polymerase chain reaction analyses confirmed the expression of AQP3 protein and messenger RNA in cell lines and tissues of lung adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056099.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 158801-98-0 / Aquaporin 3
  •  go-up   go-down


53. Chew MH, Yeo SA, Ng ZP, Lim KH, Koh PK, Ng KH, Eu KW: Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers. Int J Colorectal Dis; 2010 Oct;25(10):1221-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SRC and MA are more likely to have locally advanced lesions (T3/T4; SRC 100%, MA 90%, OA 83%, p = 0.002) and lymph node metastases (SRC 89%, MA 61%, OA 52%, p < 0.0001) and present with an advanced stage at diagnosis (stage III/IV SRC 94%, MA 67%, OA 56%, p < 0.0001).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / diagnosis. Mucins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Oct;75(2):103-7 [11064389.001]
  • [Cites] Int J Oncol. 2009 Apr;34(4):1109-15 [19287969.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):50-5 [18030531.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5660-5 [14654549.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):78-85 [14719155.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):102-7 [14752674.001]
  • [Cites] Hepatogastroenterology. 2006 Nov-Dec;53(72):845-9 [17153438.001]
  • [Cites] J Surg Oncol. 2001 Aug;77(4):282-3 [11473380.001]
  • [Cites] Gastroenterol Hepatol. 2002 Nov;25(9):534-40 [12435303.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1275-83 [16912910.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):294-8 [17693269.001]
  • [Cites] AMA Arch Surg. 1951 Jan;62(1):79-91 [14789350.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):70-4 [10694641.001]
  • [Cites] Chin Med J (Engl). 2009 Jul 5;122(13):1486-91 [19719934.001]
  • [Cites] Cancer Lett. 1996 Jun 5;103(2):163-70 [8635153.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):49-54 [8380140.001]
  • [Cites] J Pathol. 2007 Jul;212(3):278-86 [17471475.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s123-5 [15655594.001]
  • [Cites] Med Arh. 2007;61(1):26-9 [17582971.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Jan;11(1):77-81 [8672747.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1618-25 [10613484.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):160-7 [12576888.001]
  • [Cites] ANZ J Surg. 2001 Dec;71(12):703-6 [11906382.001]
  • (PMID = 20686777.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


54. Hemminki K, Santi I, Weires M, Thomsen H, Sundquist J, Bermejo JL: Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer; 2010;10:688
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes.
  • METHODS: The Swedish Family-Cancer Database has data on TNM classes on 6,105 CRC adenocarcinoma patients.
  • Young age at diagnosis was a risk factor for aggressive CRC, according to stage, N and M with odds ratios (ORs) ranging from 1.80 to 1.93 for diagnosis before age 50 years compared to diagnosis at 80+ years.
  • All tumor characteristics, particularly T, were worse for colon compared to rectal tumors.
  • The survival analysis on patients diagnosed since 2000 showed a hazard ratio of 0.55 for diagnosis before age 50 years compared to diagnosis at over 80 years and a modestly better prognosis for left-sided compared to right-sided tumors.
  • The poorer survival of old patients in colon cancer was not related to the available tumor characteristics.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2001;40(6):772-7 [11765074.001]
  • [Cites] Int J Cancer. 2010 May 15;126(10):2259-67 [19642094.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):734-42 [15010075.001]
  • [Cites] World J Surg. 2004 Jun;28(6):558-62 [15366745.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):175-9 [15615653.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2064-9 [15657655.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Sep;55(3):231-40 [15979890.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1889-99 [16344057.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2734-42 [16703598.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):13-22 [17242667.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1986-92 [17230509.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1891-7 [17488988.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):156-62 [17785761.001]
  • [Cites] Surg Innov. 2008 Mar;15(1):17-25 [18388001.001]
  • [Cites] JAMA. 2008 Jun 4;299(21):2515-23 [18523220.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2388-94 [18622647.001]
  • [Cites] Diabetes. 2008 Nov;57(11):3129-35 [18591388.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] Eur J Cancer. 2009 Apr;45(6):1006-16 [19121578.001]
  • [Cites] Eur J Cancer. 2009 Apr;45(6):1042-66 [19124239.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:227 [19594933.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Nov;72(2):155-69 [19356946.001]
  • [Cites] Fam Cancer. 2009;8(4):555-61 [19714489.001]
  • [Cites] J Natl Cancer Inst. 2010 Jan 20;102(2):89-95 [20042716.001]
  • [Cites] Acta Oncol. 2003;42(7):637-59 [14690151.001]
  • (PMID = 21176147.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022888
  •  go-up   go-down


55. Ohsawa T, Ishida H, Kumamoto K, Nakada H, Yokoyama M, Okada N, Ishibashi K, Haga N: Resection of stage 0/I colon cancer via a circumferential periumbilical skin incision: relevance to single-incision laparoscopic surgery. Tech Coloproctol; 2010 Dec;14(4):311-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of stage 0/I colon cancer via a circumferential periumbilical skin incision: relevance to single-incision laparoscopic surgery.
  • BACKGROUND: We have been performing curative resection of colon cancer via a minilaparotomy without utilizing any laparoscopic instruments as an alternative to laparoscopic-assisted approach.
  • Based on our experiences and improved surgical techniques, we have devised a new method for performing resection of stage 0/I colon cancer via a circumferential periumbilical skin incision that is associated with better cosmesis than standard minilaparotomy.
  • METHODS: The short- and long-term results of curative colectomy via a circumferential periumbilical skin incision without utilizing any laparoscopic instruments performed in selected patients with stage 0/I colon cancer between October 2003 and July 2004 were analyzed.
  • Pathological stage according the TNM classification was stage 0 in 4 patients and stage I in 6 patients.
  • CONCLUSION: Curative colectomy via a circumferential periumbilical skin incision seems oncologically safe, yields satisfactory cosmetic results, and may provide an alternative to single-incision laparoscopic surgery in selected patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparotomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] Dis Colon Rectum. 2010 Apr;53(4):496-501 [20305452.001]
  • [Cites] Colorectal Dis. 2011 Apr;13(4):393-8 [20002691.001]
  • [Cites] Endoscopy. 2001 Jul;33(7):568-73 [11473326.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] Surg Endosc. 2010 Sep;24(9):2321 [20177919.001]
  • [Cites] World J Gastroenterol. 2010 Jan 14;16(2):275-8 [20066750.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Surg Endosc. 2010 Apr;24(4):888-90 [19760335.001]
  • [Cites] Eur J Surg. 1999 Jan;165(1):29-34 [10069631.001]
  • [Cites] Dis Colon Rectum. 2010 Mar;53(3):284-8 [20173474.001]
  • [Cites] Tech Coloproctol. 2010 Jun;14(2):153-9 [20428914.001]
  • [Cites] Dis Colon Rectum. 2009 May;52(5):1021-4 [19502875.001]
  • [Cites] Surg Endosc. 2005 Mar;19(3):316-20 [15624066.001]
  • [Cites] Colorectal Dis. 2010 Jul;12(7):698-701 [19895602.001]
  • [Cites] J Laparoendosc Surg. 1991 Aug;1(4):221-4 [1834273.001]
  • [Cites] Colorectal Dis. 2010 Jan;12(1):66-70 [19508527.001]
  • [Cites] Surg Endosc. 2010 Oct;24(10):2613-6 [20364353.001]
  • (PMID = 20730550.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


56. Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, Zhan WH: [Clinical features of colorectal mucinous adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep;12(5):487-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of colorectal mucinous adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).
  • METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.
  • The rates of tumor location in colon (97 cases,57.4% vs 814 cases, 44.3%, in MAC and NMAC) were significantly different (P<0.01).
  • The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).
  • In comparison to NMAC patients, MAC patients were worse in long-term overall survival, the survival of receiving radical resection and of TNM stage (II+III) group (P<0.01).
  • Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).
  • CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.
  • Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742341.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


57. Mikhaĭlova EI, Pimanov SI, Voropaev EV: [Fecal oncomarkers in the diagnostics of colorectal cancer]. Klin Med (Mosk); 2007;85(12):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In approximately every third patient, colon cancer is revealed at stage IV, which determines the patient's outcome.
  • Early diagnosis is possible only at the pre-clinical stage.
  • Immunochemical occult blood test proved to be more sensitive for the detection of polyps or any kind of colon dysplasia (p < 0.05).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / diagnosis. Feces / chemistry. Leukocyte L1 Antigen Complex / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318171.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


58. Hines RB, Shanmugam C, Waterbor JW, McGwin G Jr, Funkhouser E, Coffey CS, Posey J, Manne U: Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer; 2009 Dec 15;115(24):5798-806
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer.
  • BACKGROUND: There is a survival disparity between African Americans and Caucasians who have colon cancer.
  • METHODS: Data from patients (n=496) who underwent surgery for a first primary colon cancer at the University of Alabama at Birmingham Hospital from 1981 to 2002 were analyzed.
  • The confounding influence of comorbidity and BMI for the increased risk of death associated with African-American race was evaluated, and effect modification by disease stage for the association of comorbidity and BMI with mortality also was assessed.
  • The effect of comorbidity was observed among those with early stage tumors, whereas the effect of BMI was confined to patients who had advanced tumors.
  • CONCLUSIONS: Although comorbidity and BMI had an impact on the survival of patients with colon cancer after surgery, these variables were not contributing factors to the decreased survival observed among African Americans.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / mortality. African Americans. Body Mass Index. Colonic Neoplasms / ethnology. Colonic Neoplasms / mortality. Comorbidity. European Continental Ancestry Group. Health Status Disparities

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [Cites] Gut. 2002 Aug;51(2):147 [12117867.001]
  • [Cites] JAMA. 2004 May 26;291(20):2441-7 [15161894.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3099-103 [15284260.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):453-71 [10717521.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1686-93 [7473817.001]
  • [Cites] J Chronic Dis. 1970 Dec;23(7):455-68 [26309916.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):668-75 [15089900.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] BMC Cancer. 2007;7:193 [17939875.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):556-65 [17823417.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2179-87 [16682737.001]
  • [Cites] J Clin Epidemiol. 1999 Feb;52(2):137-42 [10201654.001]
  • [Cites] World Health Organ Tech Rep Ser. 1995;854:1-452 [8594834.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 15;98(22):1647-54 [17105987.001]
  • [Cites] Med Clin North Am. 2005 Jul;89(4):771-93 [15925649.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Am Geriatr Soc. 1991 Aug;39(8):778-84 [1906492.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2312-20 [9635522.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Oral Oncol. 2005 Apr;41(4):358-64 [15792607.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):484-95 [12879464.001]
  • (PMID = 19937953.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / 5-RF25-CA47888; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / R25 CA047888; United States / NCI NIH HHS / CA / R01-CA98932-01; United States / NCI NIH HHS / CA / U54-CA118948; United States / NCI NIH HHS / CA / R01 CA098932-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS140672; NLM/ PMC2795032
  •  go-up   go-down


59. Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA: Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther; 2005 May;4(5):548-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the time of preparation of this manuscript, 20 patients with metastatic pancreatic cancer and one patient with metastatic colon cancer have undergone a rapid autopsy in association with the GICRMDP.
  • In an initial survey of KRAS2, TP53 and DPC4 genetic status in lethal metastatic pancreatic cancers, activating KRAS2 mutations were detected in 82% of cases and inactivating TP53 mutations in 55% of cases, consistent with rates of genetic alteration of these genes in early stage pancreatic cancers.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8516-20 [15623633.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1038-45 [10741732.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96 [11072167.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3254-7 [11248065.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 2001 May;233(5):696-703 [11323508.001]
  • [Cites] Curr Opin Oncol. 2002 Jul;14(4):424-30 [12130928.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):607-13 [12642681.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2585-8 [12750283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Int J Gastrointest Cancer. 2003;33(2-3):155-64 [14716065.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):651-7 [15277238.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Nature. 1980 Jan 10;283(5743):139-46 [6985715.001]
  • [Cites] Nucleic Acids Res. 1988 Aug 25;16(16):7773-82 [3047672.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2761-4 [8168108.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3025-33 [8187092.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]
  • [Cites] Arch Surg. 1995 Feb;130(2):125-34 [7848081.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4670-5 [7553647.001]
  • [Cites] Pancreas. 1995 Nov;11(4):345-9 [8532650.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2339-42 [9622070.001]
  • (PMID = 15846069.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106610-02; United States / NCI NIH HHS / CA / K08 CA106610; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / K08 CA106610-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS147166; NLM/ PMC2771924
  •  go-up   go-down


60. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D: Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer; 2010;10:691
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
  • BACKGROUND: The Oncotype DX Colon Cancer Assay is a new diagnostic test for determining the likelihood of recurrence in stage II colon cancer patients after surgical resection using fixed paraffin embedded (FPE) primary colon tumor tissue.
  • By capturing the biology underlying each patient's tumor, the Oncotype DX Colon Cancer Assay provides a Recurrence Score (RS) that reflects an individualized risk of disease recurrence.
  • CONCLUSIONS: Analytical performance characteristics shown here for both individual genes and gene groups in the Oncotype DX Colon Cancer Assay demonstrate consistent translation of specific biology of individual tumors into clinically useful diagnostic information.
  • The results of these studies illustrate how the analytical capability of the Oncotype DX Colon Cancer Assay has enabled clinical validation of a test to determine individualized recurrence risk after colon cancer surgery.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Genetic Testing / methods. Molecular Diagnostic Techniques. Neoplasm Recurrence, Local / genetics. Precision Medicine. Reverse Transcriptase Polymerase Chain Reaction


61. Nishiyama N, Yamamoto S, Matsuoka N, Fujimoto H, Moriya Y: Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case. Surg Today; 2009;39(8):728-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case.
  • To our knowledge, there is no case report of the synchronous resection of colon and ureteral carcinomas by laparoscopy, because of the rareness of this combination and the technical difficulties involved.
  • We report a case of simultaneous descending colon and left ureteral carcinomas, both of which were judged to be relatively early stage carcinoma, which we resected successfully laparoscopically.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Colonoscopy. Humans. Laparoscopy. Male. Urography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Surg Today. 2007;37(11):1004-8 [17952536.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):364-70 [10955865.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2007 Aug;17 (4):283-6 [17710049.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10 Suppl):S30-6 [17106813.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Jun;14(3):179-81 [15245672.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Urol. 2005 Apr;173(4):1102-7 [15758710.001]
  • [Cites] Can J Surg. 2007 Feb;50(1):48-57 [17391617.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):92-3 [15668786.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):382-6 [14712100.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2006 Jun;16(3):297-300 [16796445.001]
  • [Cites] Urology. 2001 Jan;57(1):133-7 [11164158.001]
  • (PMID = 19639445.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Sultan I, Rodriguez-Galindo C, El-Taani H, Pastore G, Casanova M, Gallino G, Ferrari A: Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases. Cancer; 2010 Feb 1;116(3):758-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common sites of involvement were the rectum (27%) and the transverse colon (26%).
  • Adenocarcinoma was the most common histotype in both adults and pediatric patients; however, children/adolescents had more unfavorable histotypes (ie, mucinous adenocarcinoma [22%] and signet ring cell carcinoma [18%]) when compared with adults (10% and 1%, respectively; P < .001).
  • Poorly differentiated and undifferentiated tumors (grades III and IV, respectively) and distant stage were more common in children/adolescents (P < .001).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • (PMID = 19957323.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Kitano S, Shiraishi N, Uyama I, Sugihara K, Tanigawa N, Japanese Laparoscopic Surgery Study Group: A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg; 2007 Jan;245(1):68-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, 1212 patients (93.7%) had stage IA disease, 75 (5.8%) had stage IB disease, and 7 (0.5%) had stage II disease (the UICC staging).
  • The 5-year disease-free survival rate was 99.8% for stage IA disease, 98.7% for stage IB disease, and 85.7% for stage II disease.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Laparoscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1800-8 [10430349.001]
  • [Cites] J Am Coll Surg. 1997 Apr;184(4):373-7 [9100682.001]
  • [Cites] Adv Surg. 1999;33:69-93 [10572562.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1647-50 [8932349.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):360-8 [8658220.001]
  • [Cites] Br J Surg. 1997 Nov;84(11):1567-71 [9393281.001]
  • [Cites] J Surg Res. 1999 Jan;81(1):27-32 [9889053.001]
  • [Cites] Ann Surg. 1999 Jan;229(1):49-54 [9923799.001]
  • [Cites] Cancer. 1999 May 15;85(10):2119-23 [10326688.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):217-22 [11227938.001]
  • [Cites] Gastric Cancer. 2001;4(2):93-7 [11706767.001]
  • [Cites] Gastric Cancer. 2001;4(2):98-102 [11706768.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] Surg Endosc. 2002 Mar;16(3):540-4 [11928051.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1145-9 [12209244.001]
  • [Cites] J Am Coll Surg. 2003 Jan;196(1):75-81 [12517554.001]
  • [Cites] Gastric Cancer. 2003;6(1):64-8 [12673429.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):968-71 [12658427.001]
  • [Cites] J Am Coll Surg. 2003 Sep;197(3):372-8 [12946791.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1440-4 [12820059.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):933-8 [15194075.001]
  • [Cites] Br J Surg. 1990 Dec;77(12):1330-4 [2276010.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):445-50 [8261986.001]
  • [Cites] Surg Laparosc Endosc. 1994 Apr;4(2):146-8 [8180768.001]
  • [Cites] Surg Laparosc Endosc. 1995 Oct;5(5):359-62 [8845979.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • (PMID = 17197967.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1867926
  •  go-up   go-down


64. Kojima M, Nakajima K, Ishii G, Saito N, Ochiai A: Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol; 2010 Sep;34(9):1351-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinicopathologic analysis revealed that peritoneal elastic laminal invasion was associated with higher tumor stage, palliative resection, deeper tumor invasion, deeper ulceration, over 5 mm of muscular layer elevation and peritoneal surface retraction with fibro-inflammation, higher budding grade, and high grade of lymphovascular invasion (P<0.01).
  • Peritoneal elastic laminal invasion was associated with recurrence and prognosis in colon cancer and was an independent risk factor for the recurrence of stage II colon cancer.
  • Peritoneal elastic lamina was useful hallmark to determine the level of tumor invasion, and was powerful indicator to predict prognosis in colon cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Neoplasm Invasiveness. Peritoneum / pathology. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Mar;35(3):465-8; author reply 468-9 [21317719.001]
  • (PMID = 20716999.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Fernandes LC, Kim SB, Matos D: Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol; 2005 Feb 7;11(5):645-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.
  • AIM: To evaluate the serum levels of cytokeratins and carcinoembryonic antigen (CEA) in diagnosis, staging and prognosis of patients with colorectal adenocarcinoma.
  • RESULTS: In the diagnosis of patients with colorectal adenocarcinoma, CEA showed a sensitivity of 56%, a specificity of 95%, a positive predictive value of 94%, a negative predictive value of 50% and an accuracy of 76.8%.
  • There was a statistically significant difference between the patients with stage IV lesions and those with stages I, II and III tumors.
  • With regard to CEA, the average level was 14.2 ng/mL in patients with stage I lesions, 8.5 ng/mL in patients with stage II lesions, 8.0 ng/mL in patients with stage III lesions and 87.7 ng/mL in patients with stage IV lesions.
  • In relation to TPA-M, the levels were 153.1 U/L in patients with stage I tumors, 106.5 U/L in patients with stage II tumors, 136.3 U/L in patients with stage III tumors and 464.3 U/L in patients with stage IV tumors.
  • CONCLUSION: Cytokeratins demonstrate a greater sensitivity than CEA in the diagnosis of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / pathology. Keratins / blood. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655814.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC4250731
  •  go-up   go-down


66. Rigopoulos DN, Tsiambas E, Lazaris AC, Kavantzas N, Papazachariou I, Kravvaritis C, Tsounis D, Koliopoulou A, Athanasiou AE, Karameris A, Manaios L, Sergentanis TN, Patsouris E: Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis. J BUON; 2010 Jan-Mar;15(1):107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis.
  • PURPOSE: Overexpression of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in colon adenocarcinoma (CA) is a frequent event, whereas specific deregulation mechanisms in the corresponding signaling pathways remain under investigation.
  • Significant associations raised correlating stage to chromosome 7 (p=0.024), HIF 1a expression to tumor anatomical location (p=0.019) and also VEGF to HIF 1a expression (p=0.001), whereas EGFR expression was not associated to EGFR gene copies.
  • [MeSH-major] Adenocarcinoma / chemistry. Colonic Neoplasms / chemistry. Hypoxia-Inducible Factor 1, alpha Subunit / analysis. Receptor, Epidermal Growth Factor / analysis. Signal Transduction. Tissue Array Analysis. Vascular Endothelial Growth Factor A / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414936.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


67. Jensen SA, Vilmar A, Sørensen JB: Adjuvant chemotherapy in elderly patients (&gt;or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis. Med Oncol; 2006;23(4):521-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
  • PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger.
  • CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence of colon carcinoma after resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] Cancer Control. 1995 Mar;2(2 Suppl 1):36-38 [10887408.001]
  • [Cites] Pharmacol Rev. 2004 Jun;56(2):163-84 [15169926.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]
  • [Cites] Lancet. 2000 May 6;355(9215):1588-96 [10821362.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):568-73 [15033660.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):103-6 [12576935.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Ann Oncol. 2005 May;16(5):767-72 [15817594.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1447-56 [2778478.001]
  • [Cites] Am J Clin Oncol. 1982 Apr;5(2):227-36 [7091044.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):947-55 [11038030.001]
  • [Cites] J Clin Oncol. 1984 Jul;2(7):849-55 [6737023.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):775-81 [7828127.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • (PMID = 17303911.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


68. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer; 2006 Oct 9;95(7):921-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study comparing normal colon to colorectal cancer by proteomics, hnRNP K was identified as being overexpressed in this type of cancer.
  • In normal colon hnRNP K was exclusively nuclear whereas in colorectal cancer the protein localised both in the cytoplasm and the nucleus.
  • There were significant increases in both nuclear (P=0.007) and cytoplasmic (P=0.001) expression of hnRNP K in Dukes C tumours compared with early stage tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Ribonucleoproteins / biosynthesis


69. Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M: Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg; 2007 Aug;246(2):215-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY BACKGROUND DATA: The incidence of rectal cancer increases with older age, and localized disease can be curatively treated with stage-appropriate radical surgery.
  • METHODS: Patients with localized rectal adenocarcinoma were identified in the Surveillance, Epidemiology, and End Results database (1991-2002).
  • Each half-decade increase in age > or =70 years was associated with a 37% increase in the relative risk (RR) for cancer-related mortality (RR = 1.37; 95% confidence interval [CI], 1.33-1.42); decreased receipt of cancer-directed surgery (odds ratio [OR] = 0.56; 95% CI, 0.36-0.63); more local excision and less radical surgery (OR = 0.76; 95% CI, 0.72-0.81); less radiotherapy (OR = 0.64; 95% CI, 0.61-0.67); and greater likelihood of N0 pathologic stage classification (OR = 1.10; 95% CI, 1.05-1.15) (P < 0.0001 for each factor).
  • [MeSH-major] Adenocarcinoma / epidemiology. Rectal Neoplasms / epidemiology


70. Greenblatt DY, Weber SM, O'Connor ES, LoConte NK, Liou JI, Smith MA: Readmission after colectomy for cancer predicts one-year mortality. Ann Surg; 2010 Apr;251(4):659-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medicare beneficiaries who underwent colectomy for stage I to III colon adenocarcinoma from 1992 to 2002 were identified from the Surveillance, Epidemiology, and End Results-Medicare database.
  • Early readmission is therefore an important quality-of-care indicator for colon cancer surgery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Apr 24;160(8):1074-81 [10789599.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1418-28 [19339721.001]
  • [Cites] Health Care Financ Rev. 2000 Spring;21(3):7-28 [11481769.001]
  • [Cites] Dis Colon Rectum. 2001 Jul;44(7):942-6 [11496073.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1533-8 [11683754.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1855-9; discussion 1859-60 [11789760.001]
  • [Cites] J Am Geriatr Soc. 2001 Nov;49(11):1561-4 [11890600.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-62-8 [12187170.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):503-9 [12682545.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):432-7 [12749241.001]
  • [Cites] J Surg Oncol. 2003 Jun;83(2):68-78; discussion 78-9 [12772198.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):851-9 [12847356.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):161-7 [12894006.001]
  • [Cites] JAMA. 2003 Aug 13;290(6):773-80 [12915430.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1112-7 [14597452.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1497-504 [14648727.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):877-83 [15194068.001]
  • [Cites] J Am Coll Surg. 2004 Nov;199(5):675-9 [15501105.001]
  • [Cites] Br J Prev Soc Med. 1965 Oct;19(4):182-91 [5845379.001]
  • [Cites] Am J Med. 1991 Jun;90(6):667-74 [2042681.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Conn Med. 1995 May;59(5):263-70 [7600797.001]
  • [Cites] Health Serv Res. 1995 Aug;30(3):489-506 [7649753.001]
  • [Cites] J Qual Clin Pract. 1995 Dec;15(4):211-20 [8719060.001]
  • [Cites] Med Care. 1997 Oct;35(10):1044-59 [9338530.001]
  • [Cites] J Am Coll Surg. 1998 May;186(5):501-6 [9583689.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):416-23 [15729063.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1463-8 [15791370.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1381-7 [10566524.001]
  • [Cites] J Epidemiol Community Health. 2005 Jun;59(6):506-11 [15911648.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):629-39 [15983985.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1354-62 [16237744.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1243-52; discussion 1252-3 [17114011.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):73-9 [17197968.001]
  • [Cites] Arch Intern Med. 2007 Feb 12;167(3):258-64 [17296881.001]
  • [Cites] Am J Manag Care. 2007 Mar;13(3):157-64 [17335359.001]
  • [Cites] J Am Geriatr Soc. 2007 Mar;55(3):365-73 [17341238.001]
  • [Cites] Curr Probl Cancer. 2007 May-Jun;31(3):123-33 [17543944.001]
  • [Cites] Br J Surg. 2007 Jul;94(7):890-3 [17330930.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1316-23 [17665252.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2430-5 [18246608.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):900-8 [18181101.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):51-7 [10862195.001]
  • (PMID = 20224370.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N02-PC-15105; United States / PHS HHS / / U55/CCR921930 - 02; None / None / / UL1 RR025011-01; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCRR NIH HHS / RR / UL1 RR025011-01; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCRR NIH HHS / RR / 1UL1RR025011; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-35136
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230999; NLM/ PMC2951007
  •  go-up   go-down


71. Hörkkö TT, Tuppurainen K, George SM, Jernvall P, Karttunen TJ, Mäkinen MJ: Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int J Cancer; 2006 Apr 1;118(7):1653-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations.
  • TRbeta1 was associated with polypoid growth, presence of K-ras mutations and also with a higher WHO histological grade and advanced Dukes' stage.
  • [MeSH-major] Adenocarcinoma / physiopathology. Adenoma / physiopathology. Colorectal Neoplasms / physiopathology. Genes, ras. Thyroid Hormone Receptors beta / biosynthesis. Thyroid Hormone Receptors beta / physiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231318.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thyroid Hormone Receptors beta
  •  go-up   go-down


72. Iarŭmov N, Toshev S, Angelov K, Lukanova Ts, Gribnev P, Sokolov M: [Multiple primary carcinomas of the colon and associated extracolonic primary malignant tumors]. Khirurgiia (Sofiia); 2007;(4):5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple primary carcinomas of the colon and associated extracolonic primary malignant tumors].
  • Adenocarcinoma of the colon is the most common visceral cancer.
  • A total of 78 tumors were involved: 24 in the sigmoid, 12 transverse colon; four in the cecum; 30 in the rectum; 3 in the ascending and 5 in descending colon; 2 each in the bladder, prostate; two each in the breast, cervix, and one each in the skin, nasopharynx, lungs.
  • Survival of patients with synchronous carcinomas is not significantly different from survival of patients with same-stage solitary carcinomas.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443527.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


73. Chin CC, Wang JY, Yeh CY, Kuo YH, Huang WS, Yeh CH: Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer. Int J Colorectal Dis; 2009 Nov;24(11):1297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.
  • OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.
  • MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.
  • In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.
  • Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.
  • CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2004 Jun;27(3):304-6 [15170153.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34 [11829427.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Gut. 2006 Nov;55(11):1681 [17047131.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):59-66 [15642427.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]
  • [Cites] Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2 [18005779.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):771-5 [18079086.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1600-8 [18327530.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] Am Surg. 2004 Mar;70(3):235-40; discussion 240 [15055847.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Cancer. 1967 Nov;20(11):1976-85 [6061631.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • (PMID = 19479270.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Yang R, Cheung MC, Zhuge Y, Armstrong C, Koniaris LG, Sola JE: Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases. J Surg Res; 2010 Jun 15;161(2):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases.
  • OBJECTIVE: To study the outcomes of solid tumors of the colon and rectum in pediatric patients.
  • Tumors were identified in the right colon (45.9%), transverse colon (9.3%), left colon (20.4%), rectum (15.2%), and anal canal (1.1%).
  • The most common histology of these tumors was adenocarcinoma (35.6%), followed by carcinoid (34.1%).
  • Multivariate analysis of the cohort identified tumor stage (HR 8.39, P < 0.001 for distant disease), tumor type (signet ring HR 2.12, P = 0.025, and carcinoid HR = 0.14, P = 0.001), and surgical resection (no surgery HR 2.98, P = 0.010) as independent predictors of worse outcome.
  • CONCLUSION: In the pediatric population, solid tumors of the colon and rectum occur more frequently in the right side of the colon in teenagers.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19285688.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Mori T, Hirota T, Ohashi Y, Kodaira S, Prospective Trial of Adjuvant Chemotherapy for Colon Cancer Study Group (PAC): Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. Dis Colon Rectum; 2006 Jul;49(7):982-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
  • PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.
  • METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.
  • CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625329.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


76. Blum C, Graham A, Yousefzadeh M, Shrout J, Benjamin K, Krishna M, Hoda R, Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace M, Mitas M: The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol; 2008 Sep;33(3):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.
  • The tumor samples were extracted from formalin-fixed paraffin-embedded primary tissues derived from patients with Stage II CRC who developed disease recurrence within two years (n=10), or were disease-free for at least 4 years (n=12).
  • This suggests that the expression ratio of Map7/B2M may serve as a valuable prognostic marker in patients with Stage II colon cancer, and potentially guide therapeutic decision making.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1332-42 [10837026.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):887-95 [17235506.001]
  • [Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):202-19 [11198882.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):719-25 [14766275.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]
  • [Cites] J Immunol. 1989 Jan 1;142(1):352-8 [2462591.001]
  • [Cites] J Exp Med. 1989 Jan 1;169(1):309-14 [2642530.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1201-4 [1737380.001]
  • [Cites] J Cell Biol. 1995 Nov;131(4):1015-24 [7490279.001]
  • [Cites] Tumori. 1997 Jan-Feb;83(1 Suppl):S39-41 [9154066.001]
  • [Cites] Inflamm Bowel Dis. 1998 Aug;4(3):196-202 [9741021.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7 [16609019.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2849-54 [17504982.001]
  • [Cites] CA Cancer J Clin. 2007 May-Jun;57(3):168-85 [17507442.001]
  • [Cites] Biotechniques. 2000 Sep;29(3):548-50, 552-4, 556 passim [10997270.001]
  • (PMID = 18695889.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA093419; United States / NCI NIH HHS / CA / R21 CA097875; United States / NCI NIH HHS / CA / R33 CA097875; United States / NCI NIH HHS / CA / CA097875
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microtubule-Associated Proteins; 0 / beta 2-Microglobulin
  • [Other-IDs] NLM/ NIHMS388523; NLM/ PMC3399116
  •  go-up   go-down


77. Belyaev O, Muller CA, Uhl W: Satisfactory long-term results after simultaneous resection of the esophagus, stomach and pancreas. Langenbecks Arch Surg; 2009 Mar;394(2):383-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of one-stage combined operations on the pancreas and esophagus with a long-term follow-up are rarely reported.
  • RESULTS: After a successful one-stage operation consisting of esophagogastrectomy and pancreaticoduodenectomy, a 30-month disease-free follow-up with a good quality of life has been observed.
  • CONCLUSION: Complicated surgical procedures such as one-stage multiple organ resections may offer, in selected cases, satisfactory long-term results, provided that patients are treated at a high-volume center by a multidisciplinary team.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Cholangitis / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Gastrectomy. Pancreaticoduodenectomy. Pancreatitis, Chronic / surgery
  • [MeSH-minor] Anastomosis, Surgical. Appendectomy. Cholecystectomy. Colon, Descending / surgery. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Quality of Life

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2006 Feb;141(2):205-8 [16490900.001]
  • [Cites] Surg Today. 2004;34(7):623-5 [15221561.001]
  • [Cites] Surg Today. 2000;30(2):168-72 [10664342.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):933-5 [15966235.001]
  • [Cites] J Surg Oncol. 1995 Dec;60(4):277-81 [8551739.001]
  • (PMID = 18704486.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Bosch Roig CE, Roselló-Sastre E, Alonso Hernández S, Almenar Cubells D, Grau Cardona E, Camarasa Lillo N, Bautista D, Molins Palau C: Prognostic value of the detection of lymph node micrometastases in colon cancer. Clin Transl Oncol; 2008 Sep;10(9):572-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the detection of lymph node micrometastases in colon cancer.
  • INTRODUCTION AND OBJECTIVES: A study is made of the clinical repercussions of occult metastases-micrometastases (MMs+)-or isolated tumour cells (ITCs+) in the lymph nodes of patients with stage IIA and IIB colon adenocarcinoma initially considered as corresponding to N0.
  • MATERIAL AND METHODS: A retrospective study of 39 patients with stage IIA and IIB (T3-T4 N0 M0) colon adenocarcinoma, subjected to similar surgical and adjuvant chemotherapy treatment, with long and careful follow-up (minimum: 5 years, mean: 81.7 months) was performed on their previously resected lymph nodes, with the aid of new histological and immunohistochemical (cytokeratin) sections, in order to detect MMs or ITCs.
  • We encourage a detailed histological study of lymph nodes resected in patients with deep penetrating colon tumours in order to assure a pN0 status.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Colonic Neoplasms / blood. Colonic Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4232-41 [12377967.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2740-1 [14669301.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] J Surg Oncol. 2004 Mar;85(3):166-70 [14991889.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):402-6 [14976530.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):300-4 [11352302.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):917-20 [1717210.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):676-80 [17005470.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] Colorectal Dis. 2003 Mar;5(2):164-8 [12780907.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1244-9 [9788387.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):637-42 [8891622.001]
  • [Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1465-71 [9407986.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] Int J Colorectal Dis. 1998;13(2):99-102 [9638496.001]
  • (PMID = 18796374.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


79. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC: Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer; 2006;6:241
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report on the prevalence and potential clinical significance of fascin expression in relation to the progression of colorectal adenocarcinoma and to tumor cell proliferation as measured by Ki67 index.
  • In the clinically-annotated tumors, fascin immunoreactivity was more common in tumors located in the proximal colon (p = 0.009), but was not associated with age, gender, or TNM stage.
  • Patients with stage III/IV adenocarcinomas (n = 62) with strong fascin immunoreactivity had a worse prognosis than patients with low or absent fascin, (3-year overall survival of 11% versus 43% for fascin-negative patients; p = 0.023).
  • Strong and diffuse expression was seen in a subset of advanced colorectal adenocarcinomas that correlated with shorter survival in stage III and IV patients.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Carrier Proteins / biosynthesis. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Microfilament Proteins / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1947-53 [11106567.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jun;34(6):685-98 [11943599.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):233-6 [12086859.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3616-23 [12789270.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Curr Opin Cell Biol. 2004 Feb;16(1):14-23 [15037300.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Gene Expr Patterns. 2004 Oct;4(6):637-43 [15465486.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] Science. 1996 May 24;272(5265):1187-90 [8638166.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13927-31 [9391129.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):245-54 [10448112.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • [Cites] Hum Genomics. 2004 Jan;1(2):134-40 [15601541.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1533-9 [16533778.001]
  • [ErratumIn] BMC Cancer. 2011;11:488
  • (PMID = 17029629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC1615879
  •  go-up   go-down


80. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH: How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis Colon Rectum; 2005 Apr;48(4):722-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Preoperative combined chemoradiotherapy is currently the main neoadjuvant therapy used to treat locally advanced middle and low rectal adenocarcinoma.
  • METHODS: Between August 2000 and June 2003, 50 patients with biopsy-proven middle and lower rectal adenocarcinoma, with initial stage T3-T4 or N+, M0, were recruited in this series.
  • Pelvic magnetic resonance imaging was used to stage the tumor before and after combined chemoradiotherapy.
  • RESULTS: The overall predictive accuracy in T stage was 52 percent, whereas overstaging and understaging occurred in 38 percent and 10 percent of patients, respectively.
  • In N stage, accurate staging was noted in 68 percent of all patients, whereas 24 percent were overstaged and 8 percent were understaged.
  • CONCLUSION: In restaging irradiated tumors, magnetic resonance imaging had the accuracy of 52 percent in T stage and 68 percent in N stage.
  • [MeSH-major] Adenocarcinoma / pathology. Magnetic Resonance Imaging / standards. Neoplasm Staging / methods. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747073.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 56HH86ZVCT / Uracil; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Xie L, Villeneuve PJ, Shaw A: Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada. Int J Oncol; 2009 Apr;34(4):1109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada.
  • Previous studies have shown conflicting results on the prognosis of colorectal mucinous adenocarcinoma.
  • Analyses were based on 165 colorectal mucinous and 1215 non-mucinous adenocarcinoma patients who were registered at the Ottawa Regional Cancer Centre from 1994 to 1997, with follow-up extending to December 31, 2001.
  • For colon, rectum and both combined, the distribution for age at diagnosis, stage and treatment of patients with mucinous adenocarcinoma was similar to that of non-mucinous patients (all p > or = 0.12).
  • Overall, no statistically significant differences were noted in 5-year relative survival between mucinous and non-mucinous carcinoma for colon, rectum and their combination (p > or = 0.35 for each).
  • However, when the stages were considered separately, patients with stage III mucinous carcinoma had worse survival than patients with non-mucinous carcinoma for both sites.
  • Multivariate analysis of combined data for colon and rectal cancers indicated that independent significant prognostic factors were stage for mucinous, with age and grade as well as stage for non-mucinous carcinoma.
  • In conclusion, no significant differences in stage distribution and overall survival were found between mucinous and non-mucinous patients for colorectal cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287969.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


82. Abd El-Hameed A: Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst; 2005 Mar;17(1):42-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in colorectal adenocarcinoma using tissue microarray.
  • This study examined the expression, and potential prognostic value of survivin in colorectal adenocarcinoma (CRC) on tissue microarray (TMA) sections.
  • MATERIAL AND METHODS: Two-hundred and eighty cases of colorectal adenocarcinoma were arrayed.
  • There was no correlation between survivin immunoreactivity and age, sex, tumor site, tumor size, histopathologic subtype, tumor grade and clinical stage (p >0.05).
  • The 5-year disease free survival (DFS) for patients with survivin positive colorectal adenocarcinoma was significantly lower than that for patients with survivin negative tumors (46% versus 68.7%, p=0.001).
  • CONCLUSION: Survivin expression in colorectal adenocarcinoma provides an important prognostic parameter and targeted antagonists of survivin may be beneficial as apoptosis-based therapy for colon cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353082.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


83. Bianchi PP, Ceriani C, Locatelli A, Spinoglio G, Zampino MG, Sonzogni A, Crosta C, Andreoni B: Robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncological safety and short-term outcomes. Surg Endosc; 2010 Nov;24(11):2888-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From March 2008 to June 2009, 50 patients with proven middle/lower rectal adenocarcinoma underwent minimally invasive TME; 25 received R-TME.
  • The groups were balanced (R-TME versus L-TME) in terms of age (median 69 versus 62 years; p = 0.8), disease stage, and body mass index (median 23 versus 26.5 kg/m(2); p = 0.06).
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Rectal Neoplasms / surgery. Rectum / surgery. Robotics

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Dec;25(12):3954-6; author reply 3957-8 [21695585.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):26-31 [18085339.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Surg Endosc. 2005 Jul;19(7):892-6 [15920688.001]
  • [Cites] Ann Surg Oncol. 2009 Jun;16(6):1480-7 [19290486.001]
  • [Cites] BJU Int. 2009 Nov;104(10):1428-35 [19804427.001]
  • [Cites] Br J Surg. 2009 Sep;96(9):982-9 [19644973.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):275-81 [18941844.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005200 [17054246.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3168-73 [17763911.001]
  • [Cites] Ann Surg. 2009 Jul;250(1):54-61 [19561481.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] J Surg Oncol. 2007 Dec 15;96(8):660-4 [18081161.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Singapore Med J. 2009 Aug;50(8):763-7 [19710972.001]
  • [Cites] Ann Surg Oncol. 2009 May;16(5):1274-8 [19242762.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Surg Endosc. 2009 Feb;23(2):447-51 [19057962.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Dis Colon Rectum. 2008 Nov;51(11):1627-32 [18484134.001]
  • [Cites] Ann Surg Oncol. 2009 May;16(5):1279-86 [19252948.001]
  • [Cites] Dis Colon Rectum. 2009 Apr;52(4):558-66 [19404053.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • [Cites] Ann Surg Oncol. 2009 Jun;16(6):1488-93 [19290491.001]
  • [Cites] Surg Endosc. 2006 Oct;20(10):1521-5 [16897284.001]
  • [Cites] Dis Colon Rectum. 2007 Dec;50(12):2047-53 [17906896.001]
  • (PMID = 20526623.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Hornick JL, Farraye FA, Odze RD: Clinicopathologic and immunohistochemical study of small apparently "de novo" colorectal adenocarcinomas. Am J Surg Pathol; 2007 Feb;31(2):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical study of small apparently "de novo" colorectal adenocarcinomas.
  • These tumors have been termed "de novo" carcinomas.
  • The aim of this study was to evaluate and compare the pathologic features, biologic characteristics, and natural history of small apparently de novo invasive colorectal adenocarcinomas with conventional large (>1.0 cm) carcinomas.
  • Routinely processed specimens from 20 patients (M/F ratio: 13/7; mean age: 65 y) with small apparently de novo invasive colorectal adenocarcinomas (all < or =1.0 cm in size) were evaluated for a variety of clinical and pathologic features.
  • The findings in this group of cases were compared with those from 20 control patients (M/F ratio: 8/12; mean age: 60 y) with stage-matched conventional "large" colorectal adenocarcinomas (all >1.0 cm in size).
  • Small apparently de novo invasive adenocarcinomas were present in the left colon, transverse colon, and right colon in 85%, 10%, and 5% of cases, respectively.
  • All cases were stage T1 and the majority were moderately differentiated (75%).
  • In our patient population, true small de novo colorectal adenocarcinomas, tumors that lack an identifiable adenomatous component, are exceedingly rare, because complete tissue sectioning reveals residual adenomatous tissue in the majority of cases.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255765.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Yamamoto S, Yoshimura K, Konishi F, Watanabe M: Phase II trial to evaluate laparoscopic surgery for Stage 0/I rectal carcinoma. Jpn J Clin Oncol; 2008 Jul;38(7):497-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial to evaluate laparoscopic surgery for Stage 0/I rectal carcinoma.
  • Recently reported randomized controlled trials demonstrated that laparoscopic surgery (LS) was comparable or superior to open surgery with regard to the long-term outcome for colon and rectosigmoidal carcinoma; however, controversy persists with regard to the appropriateness of LS for patients with rectal carcinoma.
  • To examine the technical and oncological feasibility of LS for rectal carcinoma, a phase II trial was started in patients with a preoperative diagnosis of Stage 0/I rectal carcinoma, under the direction of the Japan Society of Laparoscopic Colorectal Surgery.
  • The primary end-point in the first stage is the anastomotic leakage rate by double-stapling technique and that in the second stage is overall survival.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Rectal Neoplasms / surgery

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586667.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


86. Ugurlu MM, Asoglu O, Potter DD, Barnes SA, Harmsen WS, Donohue JH: Adenocarcinomas of the jejunum and ileum: a 25-year experience. J Gastrointest Surg; 2005 Nov;9(8):1182-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because few large published experiences exist, we reviewed patients with jejunal and ileal adenocarcinoma treated at our institution over the last 25 years.
  • Between January 1976 and December 2001, 77 patients had an operation for a jejunal or ileal adenocarcinoma.
  • One (1%) patient had stage I, 18 (23%) stage II, 19 (25%) stage III, and 39 (51%) stage IV adenocarcinoma at diagnosis.
  • Tumor stage had a highly significant effect (P < 0.0001) on median survival (72 months for stage I and II, 30 months for stage III, and 9 months for stage IV disease).
  • In multivariate analysis of patients having curative treatment, tumor recurrence (P < 0.0001), stage (P < 0.0002), and weight loss (P < 0.001) were significant negative prognostic indicators.
  • Most patients with adenocarcinoma of the jejunum or ileum present with advanced disease.
  • Tumor stage, disease recurrence, and weight loss predicted patient outcome following a curative operation.
  • [MeSH-major] Adenocarcinoma / surgery. Ileal Neoplasms / surgery. Jejunal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Inflamm Bowel Dis. 2004 Jan;10(1):32-5 [15058524.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Am J Surg. 1986 Jun;151(6):654-8 [2424326.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Chin Med J (Engl). 2004 Jul;117(7):1045-9 [15265380.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):116-28 [3285475.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):438-41 [4007431.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):300-6 [9060587.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Ann Surg Oncol. 1994 Jul;1(4):290-5 [7850527.001]
  • [Cites] Am Surg. 2000 Jan;66(1):46-51 [10651347.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • (PMID = 16269390.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Roque VM, Forones NM: [Evaluation of the toxicity and quality of life in patients with colorectal cancer treated with chemotherapy]. Arq Gastroenterol; 2006 Apr-Jun;43(2):94-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Avaliação da qualidade de vida e toxicidades em pacientes com câncer colorretal tratados com quimioterapia adjuvante baseada em fluoropirimidinas.
  • According to the International Union Against Cancer classification, 34 patients (75.6%) had tumors stage II or III and 11 had tumors stage IV (24.4%), 64.4% were in the colon.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119662.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Yano H, Saito Y, Kirihara Y, Takashima J: Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma. Dis Colon Rectum; 2006 Dec;49(12):1867-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma.
  • METHODS: We analyzed 480 positive lymph nodes from 155 consecutive patients with Stage III colorectal cancer to determine the frequency and significance of lymph node capsular invasion.
  • CONCLUSIONS: Lymph node capsular invasion, determined by routine hematoxylin-eosin staining, is a potent prognostic factor in Stage III colorectal cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2007 Sep;50(9):1484; author reply 1484-5 [17661142.001]
  • (PMID = 17080279.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Barresi V, Grosso M, Vitarelli E, Tuccari G, Barresi G: 5-Lipoxygenase is coexpressed with Cox-2 in sporadic colorectal cancer: a correlation with advanced stage. Dis Colon Rectum; 2007 Oct;50(10):1576-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Lipoxygenase is coexpressed with Cox-2 in sporadic colorectal cancer: a correlation with advanced stage.
  • A statistically significant correlation also was observed between 5-lipoxygenase expression and tumor stage and lymph node metastasis, whereas no significant correlations emerged regarding cyclooxygenase-2 expression and clinicopathologic parameters.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Arachidonate 5-Lipoxygenase / metabolism. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / pathology. Cyclooxygenase 2 / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762961.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


90. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY: Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis; 2007 Feb;22(2):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare tumors of the colon and rectum: a national review.
  • This population-based evaluation is the first comprehensive look at four rare histologic types of CRC, allowing comparisons with the more common adenocarcinoma for clinical and pathological features and survival rates.
  • MATERIALS AND METHODS: All patients diagnosed with carcinoid (n=2,565), malignant lymphoma (n=955), non-carcinoid neuroendocrine (n=455), squamous cell (n=437), and adenocarcinoma (n=164,638) in SEER cancer database (1991-2000) were analyzed.
  • Evaluation of age-adjusted incidence rate, stage at presentation, and 5-year relative survival were determined for each histologic subtype.
  • Incidence rates in 2000 per million were: carcinoid 10.6, lymphoma 3.5, neuroendocrine 2.0, squamous 1.9, and adenocarcinoma 496.3.
  • Squamous (93.4%) and carcinoid (73.7%) tumors occurred more often in the rectum; lymphoma (79.0%), neuroendocrine (70.8%), and adenocarcinoma (70.1%) occurred more often in the colon (P<0.01).
  • Carcinoids presented at earlier stage (localized/regional, 90.5%) more often than adenocarcinoma (80.6%; p<0.01), but squamous cell (82.1%; p=0.50), lymphoma(70.6%; p<0.01), and neuroendocrine (37.8%; p<0.01) presented at earlier stage similarly or less often than adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / epidemiology. Carcinoid Tumor / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphoma / epidemiology. Lymphoma / pathology. Male. Middle Aged. Neuroendocrine Tumors / epidemiology. Neuroendocrine Tumors / pathology. Survival Analysis. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2003 Jun;12(3):191-4 [12771556.001]
  • [Cites] South Med J. 1989 Dec;82(12):1501-5 [2595419.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):258-63 [10211505.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):144-7 [1402312.001]
  • [Cites] Jpn J Surg. 1983 Jul;13(4):331-6 [6645123.001]
  • [Cites] Dis Colon Rectum. 1994 Dec;37(12):1277-80 [7995158.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Histopathology. 1988 Mar;12(3):235-52 [3366441.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] Surg Gynecol Obstet. 1986 Nov;163(5):493-6 [3775628.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-49-54 [12187168.001]
  • [Cites] Postgrad Med J. 1986 Jul;62(729):615-20 [3529065.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):341-6 [11289278.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):117-22 [15213627.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):627-33 [10492638.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):743-8 [11251169.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • (PMID = 16845516.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


91. Choi BJ, Cho YG, Song JW, Kim CJ, Kim SY, Nam SW, Yoo NJ, Lee JY, Park WS: Altered expression of the KLF4 in colorectal cancers. Pathol Res Pract; 2006;202(8):585-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Statistically, loss of KLF4 protein expression was not associated with clinocopathologic parameters, including tumor stage (Bartholomew test, P>0.05), lymph node metastasis, differentiation, tumor location, and tumor size (chi2 test, P>0.05).
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Kruppel-Like Transcription Factors / metabolism. Zinc Fingers
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Colon / metabolism. Colon / pathology. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16814484.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors
  •  go-up   go-down


92. Wakeman CJ, Dobbs BR, Frizelle FA, Bissett IP, Dennett ER, Hill AG, Thompson-Fawcett MW: The impact of splenectomy on outcome after resection for colorectal cancer: a multicenter, nested, paired cohort study. Dis Colon Rectum; 2008 Feb;51(2):213-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study was designed to determine whether incidental splenectomy for iatrogenic injury affects long-term cancer-specific survival in patients having resection of an adenocarcinoma of the sigmoid or rectum.
  • Data were analysed for age, American Society of Anesthesiologists physical status, gender, disease stage, operation type, and outcome.
  • These cases were matched with patients from the same center, of the same age and gender, with the same stage of disease and operation, who did not require a splenectomy at the time of their surgery.
  • Matched gender, stage, and American Society of Anesthesiologists-matched controls were identified.
  • DISCUSSION: Patients with colorectal cancer who had splenectomy as a result of iatrogenic damage of the spleen while undergoing resection of the sigmoid or rectum for adenocarcinoma had a significantly worse prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / surgery. Intraoperative Complications. Spleen / injuries. Splenectomy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2008 Sep;51(9):1440; author reply 1441-2 [18521672.001]
  • (PMID = 18176826.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


93. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol; 2010 Jan 20;28(3):466-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
  • We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting.
  • RESULTS: KRAS and BRAF tumor mutation rates were 37.0% and 7.9%, respectively, and were not significantly different according to tumor stage.
  • In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10(-4)).
  • CONCLUSION: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


94. Törnroos A, Garvin S, Olsson H: The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer. Acta Oncol; 2009;48(8):1152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer.
  • BACKGROUND. The positive correlation between the number of recovered benign lymph nodes and patient prognosis is well established for stage II colon cancer patients.
  • One theory explaining this correlation focuses on potential understaging of cancer specimen, implying that a specimen with few examined lymph nodes is likely to be assigned a lower N-stage than the correct one.
  • This study aims to investigate the association between the total lymph node harvest and the number of lymph node metastases in colon cancer specimen.
  • We studied the original pathology reports of 649 patients diagnosed with T3 adenocarcinoma of the colon at the Department of Clinical Pathology and Genetics at Linköping University Hospital, Linköping, Sweden between the years 2000 and 2008.
  • Rather than focusing on a recommended minimum number of nodes, efforts should be shifted towards developing methods assuring that colon cancer specimen are dissected in a standardized way that optimizes the lymph node harvest.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863223.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Schwandner O, Schlamp A, Broll R, Bruch HP: Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis; 2007 Feb;22(2):127-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were sporadic rectal adenocarcinoma resected curatively (including total mesorectal excision), adjuvant radiochemotherapy in UICC stages II and III, and complete intra-institutional follow-up.
  • Neither pattern correlated with age, gender, tumor stage (UICC), grading, preoperative serum carcinoembryonic antigen (CEA) level, or nodal status (p>0.05).
  • In terms of survival, preoperative CEA level (disease-free 5-year survival 46% with increased CEA vs 70% with normal CEA, p=0.01; overall 5-year survival 43 vs 74%, p<0.01) and UICC stage were the only factors to be significantly related to 5-year survival by univariate analysis, whereas the metalloproteinases failed to show a significant association.
  • In multivariate analysis, CEA and UICC stage were not identified as independent factors predictive of survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Matrix Metalloproteinase 14 / biosynthesis. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Rectal Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2004;200(5):379-87 [15239346.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):239-46 [1646457.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):220-5 [8008747.001]
  • [Cites] Br J Cancer. 1997;76(6):805-11 [9310250.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1317-21 [11355941.001]
  • [Cites] J Korean Med Sci. 1999 Aug;14(4):417-23 [10485622.001]
  • [Cites] Dis Colon Rectum. 1999 May;42(5):559-62 [10344676.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Sep;104(9 Pt 1):678-84 [7661515.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1153-62 [9740080.001]
  • [Cites] Int J Cancer. 2001 Sep 20;95(5):290-4 [11494227.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):518-24 [15103490.001]
  • [Cites] Gut. 1999 Aug;45(2):252-8 [10403738.001]
  • [Cites] Jpn J Clin Oncol. 1996 Oct;26(5):303-9 [8895669.001]
  • [Cites] FASEB J. 1999 May;13(8):781-92 [10224222.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):245-52 [15592677.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):324-9 [9440760.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3046-50